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ABSTRACT  
Immune checkpoint blockade results in T cell antitumor responses but most 
patients fail to respond. This raises fundamental questions about mechanisms of tumor 
immune recognition and resistance. Here, I first report tumor regressions in a subset of 
patients with metastatic melanoma treated with anti-CTLA4 antibody and radiation (RT) 
and reproduced this effect in mouse models. Although combined treatment improved 
responses in irradiated and unirradiated tumors, resistance was common due to 
upregulation of PD-L1 on tumor cells and corresponding T cell exhaustion. Accordingly, 
optimal response in melanoma and other cancer types required RT, anti-CTLA4, and 
anti-PD-L1/PD1. When I investigated determinants of improved responses to 
combination therapy, I found that RT enhanced the antigenic diversity of intratumoral T 
cells, anti-CTLA4 predominantly inhibited regulatory T cells, and anti-PD-L1 reversed T 
cell exhaustion. I next extended my investigation of this combination therapy to 
pancreatic ductal adenocarcinoma (PDA), finding that optimal responses required 
addition of agonist CD40 monoclonal antibody. To further understand determinants of 
response and resistance in PDA, I next examined the immune landscape of PDA in 
humans. I report that human PDA displays a range of intratumoral cytolytic T cell 
activity: PDA tumors with low cytolytic activity exhibited significantly increased copy 
number alterations, high cytolytic activity in PDA did not correlate with increased 
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neoepitope load, and PDA tumors exhibited a unique pattern of immune suppressive 
molecule expression. To place PDA in a wider context of human adaptive antitumor 
immunity, I then extended this analysis to 35 solid tumor types, finding abundant 
neoepitopes across human cancer at the global level and identifying immune gene sets 
predictive of neoepitope load. Overall, distinct rates of neoepitope generation, cytolytic 
activity, and immune suppressive molecule expression define disease types across human 
cancer. In summary, these findings characterize mechanisms of response and resistance 
to immune checkpoint blockade in distinct tumor types and investigate determinants of 
adaptive immunity in human cancer. 
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CHAPTER 1 - Introduction  
Immunosurvelliance and the cancer immunoediting hypothesis 
Leukocytes in the tumor microenvironment exert critical influence on the process 
of oncogenesis, playing a dual role of both promoting and suppressing tumor growth 
through complex, dynamic interactions (Hanahan & Weinberg 2011). Paul Ehrlich first 
suggested in 1909 that immune function could, under normal homeostasis, exert control 
over clinically significant disease in a manner similar to the highly efficient and sensitive 
immune control of infections (Ehrlich 1909). This hypothesis was refined by Burnet and 
Thomas half a century later when they proposed that ‘immune surveillance’ could 
restrain early malignant lesions by recognizing and destroying nascent tumor cells, and 
then subsequently proposed that such a mechanism may be required for survival of long-
lived organisms (Burnet 1957, Cellular and Humoral Aspects of the Hypersensitive States: 
A Symposium at the New York Academy of Medicine 1959). Interest in these early 
theories was renewed by Schreiber et al. in 2001 when he showed that newly-available 
immunodeficient lacking key adaptive immune proteins (interferon-γ and perforin) had 
increased incidence of tumors (Shankaran et al. 2001) . This discovery led to a refinement 
by Schreiber et al. of the immune surveillance concept into the current paradigm of 
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immune-tumor interaction, the cancer immunoediting hypothesis (Dunn et al. 2004). 
This hypothesis recognizes both tumor-promoting and host-protective immune effects 
and is codified into three temporally distinct phases: immune elimination, immune 
equilibrium, and immune escape. 
The elimination phase is Burnet and Thomas’ immune surveillance hypothesis 
revisited, and is the first and most prevalent interaction between the host immune system 
and tumor. The mechanisms of initial immune activation against tumors are diverse and 
incompletely understood, but this process likely requires the coordination of innate and 
adaptive cell types, beginning with the release of ‘danger signals’ in a process analogous to 
that during infection (Gallucci & Matzinger 2001). For instance, early tumor 
development results in release of type I interferons, (Dunn et al. 2005) and various 
damage-associated molecular patterns or stress ligands can be released directly from 
dying tumor cells or due to disruption of surrounding stroma (Sims et al. 2010). This 
initial activating signal is subsequently propagated by local release of proinflammatory 
cytokines such as interferon-γ, leading to increased recruitment of innate immune 
populations that result in a local environment conducive to immune priming (Guerra et 
al. 2008). Following activation of naïve CD4 and CD8 T cells, CD8 effector T cells 
infiltrate the tumor site and directly engage tumor cells in a MHC class I-dependent 
manner. This destruction mechanism is reliant on continued expression of tumor-
specific antigen and MHC; thus, the determinants of whether immune elimination is 
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successful depends on the profile of available tumor antigens as well as the sustained 
existence of a proinflammatory milieu that supports T cell effector function. 
Nascent malignant cells occasionally avoid this early immune-mediated 
destruction, leading to a relatively rare state of equilibrium between host and tumor. In 
this phase, a dynamic balance exists in which overall tumor outgrowth is restrained by the 
immune system but complete eradication never occurs. Entrance into the equilibrium 
phase is likely marked by selection of relatively low immunogenicity tumor clones; 
however, enough immune pressure exists to sustain the equilibrium state for extended 
periods of time. In humans, transfer of undetected cancer from an organ donor into 
immunosuppressed recipients can occur (MacKie et al. 2003) and dormant tumor cells 
can exist in patients for several decades before resuming growth (Aguirre-Ghiso 2007). 
That this period of time can stretch into years implies that the most prevalent state of the 
tumor microenvironment from an immune standpoint is one in which tumor cells are 
unable to accumulate sufficient adaptation to become clinically detectable. In 
immunocompetent mice exposed to carcinogen, tumor cells can apparently exist for 
extended periods of time, only developing into clinically detectable masses upon 
depletion of T cells and blockade of interferon-γ (Koebel et al. 2007). Additional evidence 
of an equilibrium phase comes from the finding that antigen-specific T cells can suppress 
pancreatic tumors in a Tag-induced carcinogenesis model, dependent on tumor necrosis 
factor and interferon-γ (Müller-Hermelink et al. 2008). In this study, in the absence of 
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these proinflammatory factors, T cells promoted angiogenesis and multistage 
carcinogenesis, denoting the primary important of maintaining a local proinflammatory 
milieu. Continued expression of tumor antigen is not sufficient for arresting tumor 
growth, a principle that has profoundly impacted therapeutic attempts to augment 
endogenous immunity. 
The escape phase occurs when growth of tumor cells progress into a clinically 
significant mass, unrestrained by host immune function. This state arises due to a 
combination of acquired tumor immune privilege, immune-intrinsic limitations in 
response, active tumor-induced immunosuppression, and direct resistance to destruction 
by T cells, that together result in progression out of the equilibrium phase. First, acquired 
tumor immune privilege is a state of inadequate recognition by the immune system of 
tumor cells, (Mellor & Munn 2008) and has been demonstrated to occur after loss of 
antigen expression against which CD8 effector T cells are directed. This can be due to 
selection of tumor cells that no longer produce highly immunogenic proteins, have 
inadequately functioning antigen-processing machinery, or have downregulated MHC 
class I. Intrinsic tumor cell genetic instability provides a fertile ground for selection of 
these T cell-resistant clones. 
Second, upregulation of immune suppression, both through pathways intrinsic to 
the immune system designed to prevent unrestrained activation and through active co-
option of these same pathways by tumor cells, are key contributors to immune escape. 
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Immune suppressive cytokines such as vascular endothelial growth factor, transforming 
growth factor-beta or indoleamine 2,3-dioxygenase, and a plethora of newly identified or 
recently established molecules, can potently suppress adaptive immunity by directly 
limiting effector cell trafficking and function or by promoting suppressive populations 
such as regulatory T cells and myeloid-derived suppressor cells (Mittal et al. 2014). A 
major additional axis of immune suppression is through the increased expression of 
immune checkpoint pathways such as CTLA4 and PD1/PD-L1. In the case of immune 
checkpoints, increased signaling occurs both in direct response to a T cell-inflamed 
microenvironment and due to increased oncogene-driven ligand expression by tumor 
cells (Pardoll 2012).  
Third, direct resistance to T cell cytolytic function can occur through 
upregulation of pro-survival molecules that prevent apoptotic cell death. Tumor cells 
under selective immune pressure are shown to upregulate molecules such as STAT3 or 
the anti-apoptotic molecule Bcl2 (Gajewski et al. 2011). Apoptotic cell death is regulated 
in a complex manner by interactions between pro-survival and pro-apoptotic molecules. 
This provides ample evolutionary surface for tumor cell adaptation. Furthermore, 
aberrations in these same pathways are often cancer-initiating events, increasing the 
likelihood that cancer cells are intrinsically resistant to T cell effector function (Fernald & 
Kurokawa 2013). Taken together, these three categories of tumor escape mechanisms 
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ensure that clinically significant tumors have, in most cases, a long history of selection for 
immune-evasive properties at the time of clinical presentation. 
The central tenet of the cancer immunoediting hypothesis is that T cell 
recognition of specific antigens drives immune elimination. This is supported by the 
finding that RAG2-deficient mice lacking T cells harbor more immunogenic tumors 
(Schreiber et al. 2011). In theory, non-synonymous somatic mutations, whether drivers of 
malignancy or passengers accrued during oncogenesis, are a source of mutated peptides 
distinct from self tissue. No tolerance against such peptides, termed neoepitopes, is likely 
to exist because they are not expressed in the thymus during T cell development and are 
not a substrate of peripheral tolerance mechanisms in normal tissue. In two landmark 
2012 studies investigating the antigenicity of nascent tumor cells, neoepitopes were 
sufficient to induce antitumor immunity and selected against during tumor growth 
(DuPage et al. 2012, Matsushita et al. 2012). Matsushita et al. demonstrated that 
carcinogen-induced sarcomas in RAG2-deficient mice harbored a point mutation in 
Spectrin-beta2 capable of subsequently driving tumor rejection in immune competent 
mice, demonstrating immune selection against a neoepitope. DuPage et al. demonstrated, 
using a autochthonous murine sarcoma model, that primary tumors from similarly 
immunodeficient mice were edited to become less immunogenic in immunocompetent 
mice (DuPage et al. 2012). Additionally, using the neoepitope pipeline described in this 
thesis, colleagues and I reported that a lack of immune editing could be reversed in a 
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murine model of PDA with the addition of a single highly immunogenic neoantigen 
(Evans et al. 2016). Taken together, these results established the primacy of neoepitopes 
in immune surveillance, implying these may also be critical in augmenting antitumor 
immunity therapeutically. 
Several lines of evidence support the immunoediting hypothesis’ relevance to 
human disease. First, patients who are immunosuppressed after organ transplant or due 
to AIDS exhibit higher incidence of tumors than the general population, suggesting that 
adaptive immune function exerts a large effect on background rate of tumorigenesis 
(Vesely et al. 2011). In particular, the dramatically increased frequency of virus-associated 
malignancies in AIDS patients may reflect the relatively efficient elimination of these 
immunogenic cells in normal individuals (Boshoff & Weiss 2002). Second, correlative 
clinical evidence from diverse disease types shows that the presence of CD8 tumor-
infiltrating lymphocytes (TILs) is associated with improved clinical outcome (Clemente et 
al. 1996, Naito et al. 1998, Zhang et al. 2003). Third, in rare but well-documented cases, 
patients with cancer can develop profound, spontaneous adaptive immune responses to 
non-viral antigens expressed by tumors (Boon & van der Bruggen 1996). Of course, 
recent clinical breakthroughs using combinatorial blockade of specific negative adaptive 
immune checkpoints provides significant evidence of baseline immune activity in tumors, 
consistent with the immunoediting hypothesis (Brahmer et al. 2012, Hamid et al. 2013, 
Hodi et al. 2010, Postow et al. 2015b, Schadendorf et al. 2015, Topalian et al. 2015).  
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Recent investigations have also provided mechanistic insight into cancer 
immunoediting in humans. First, whole exome sequencing of non–small cell lung cancers 
treated with antibodies that block negative immune checkpoints demonstrated that 
therapeutic efficacy correlated with higher nonsynonymous mutation and neoepitope 
burden (Rizvi et al. 2015). Rizvi et al. additionally found that total exonic mutation 
burden was a poorer correlation of response, implying that neoantigens derived from 
somatic missense mutations – not overall genomic errors or instability, which may 
correlate strongly with tumor aggressivity– is an important factor in predicting response 
to therapy. Similarly, responses to anti-CTLA4 in patients with metastatic melanoma 
similarly correlated with overall mutation and neoepitope load (Van Allen et al. 2015). 
Here, durable response, despite initial fluctuations in disease, correlated with these 
measures as well as tumor cytolytic activity as assessed by expression of granzyme A and 
perforin, a pattern consistent with partial reversion to a state of immune equilibrium. 
These studies specifically support the hypotheses that neoepitope-directed T cells are of 
primary importance to therapeutic induction of antitumor immunity in humans, and 
when taken together with studies of immune interactions with nascent tumors, support 
the hypothesis that the immune system exerts continuous impact on tumor biology.  
In summary, the cancer immune editing hypothesis is the underlying framework 
for much of the current field of cancer immunology. This includes work discussed in 
chapters 3 (page 63), which investigates mechanisms of resistance to immunity acquired 
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by tumors in response to immune pressure, and Chapter 4 (page 103), which investigates 
immune determinants and recognition of tumors by T cells across human cancer (Figure 
1). 
 
Figure 1. The cancer immune editing hypothesis. 
This hypothesis states that early during tumorigenesis, nascent tumor cells result 
in an upregulation of inflammatory signals, leading to an effective T cell response and 
tumor elimination (top). However, this process can go awry; tumors escape this immune-
mediated destruction, leading to clinically significant disease (bottom). For the purpose of 
this dissertation, tumor escape can occur either through the active upregulation in the 
tumor microenvironment of immune suppressive pathways or a state of acquired 
immune privilege (red). These processes can be reversed therapeutically with immune 
checkpoint blockade or immune agonist strategies (blue). This immune biology is 
investigated in Chapters 3 and 4.  
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Negative immune checkpoints and cancer 
Cytotoxic T-lymphocyte-associated protein 4 
It is now well understood that immunotherapy capable of stimulating CD8 
effector T cells can eradicate established tumors in mice and humans. Yet even in the 
setting of immune-stimulating agents such as vaccines, tumors often escape destruction. 
This likely occurs through further selection, now in the therapeutic setting, for 
suppressive mechanisms similar to those that result in initial escape from endogenous 
immunity. Understanding these suppressive mechanisms is of great importance for 
improving immune therapy. The most notable therapeutically-leveraged immune 
suppressive pathway is CTLA4, a critical regulator of T cell activation. Early work first 
demonstrated that CTLA4 knockout mice rapidly succumb to lymphoproliferative 
disease with concomitant T cell infiltration in multiple organ systems (Pardoll 2012, Tivol 
et al. 1995, Waterhouse et al. 1995). CTLA4 primarily counteracts the T cell co-
stimulatory receptor CD28, which during T cell activation provides a required amplifying 
signal to TCR stimulation (Linsley et al. 1990, 1991). CD28 and CTLA4 have identical 
ligands, CD80 and CD86, which bind CTLA4 with greater affinity; thus, interaction with 
CTLA4 outcompetes that with CD28 when CTLA4 expression is induced (Schneider et al. 
2006). Despite this role of CTLA4 expression on effector CD8 T cells, the predominant 
mechanism by which CTLA4 dampens adaptive immunity is by augmenting regulatory T 
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cell suppressive function and limiting CD4 T cell activity (Lenschow & Walunas 1996, 
Peggs et al. 2009, Wing et al. 2008). CTLA4 is a target of FOXP3, the regulatory T cell 
master transcription factor, regulatory T cells constitutively express CTLA4, (Gavin et al. 
2007, Hill et al. 2007) and CTLA4 signaling in this cell population promotes suppressive 
functions such as production of transforming growth factor beta (Chen et al. 1998). 
Consistent with these mechanisms, blockade of CTLA4 was demonstrated in a landmark 
study by Allison and colleagues to significantly improve antitumor T cell responses in 
mice bearing moderately immunogenic tumors in which some baseline, endogenous 
immunity is present (Leach et al. 1996).  
Based on this work and other preclinical models, two humanized anti-CTLA4 
antibodies began clinical testing in 2000, (Hodi et al. 2003) producing objective responses 
in approximately 10% of patients despite severe immune related adverse events (Phan et 
al. 2003). A subsequent randomized, three-arm clinical trial showed a 3.5-month overall 
survival benefit in patients with metastatic melanoma treated with anti-CTLA4 (Hodi et 
al. 2010). Interestingly, an accompanying vaccine against the universal melanoma antigen 
GP100 did not further improve responses, suggesting that re-direction of immunity 
against known antigens was not essential for response. This objective response rate 
corresponded to an improvement in long-term survival of 18% at two years, a highly 
impressive durability of response that serves as a foundation for the promise of immune 
checkpoint blockade to revert some advanced tumors to a state of immune equilibrium. 
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Programmed cell death protein 1 
Leading the class of emerging, second-generation immune therapies is blockade of 
programmed cell death protein 1 (PD1). Therapeutic antibodies against PD1 or its ligand 
PD-L1 have produced objective responses in patients with melanoma, non-small cell lung 
cancer, and other malignancies (Brahmer et al. 2012, Topalian et al. 2012). Like CTLA4, 
PD1 is expressed principally on T cells. Unlike CTLA4, which reduces the amplitude of T 
cell activation, PD1 primarily appears to limit the function of already activated T cells 
(Pardoll 2012), and the PD1 ligands PD-L1 and PD-L2 are upregulated on a plethora of 
cells during inflammation, including tumor cells. PD-1 ligation can result directly in 
apoptosis of activated T cells, (Dong et al. 2002) yet other effects are more complex, 
involving at least 5 interacting molecules that induce transition to an anergic state in 
activated T cells (Barber et al. 2006, Goldberg et al. 2007). The PD1/PD-L1 pathway also 
augments suppressive regulatory T cells, a second mechanism by which this pathway 
influences immune responses (Dong et al. 1999). These insights led to the hypothesis that 
PD-1 pathway blockade might extend antitumor T cell function, was which proven to be 
the case in several preclinical murine models (Curiel et al. 2003). The FDA recently 
approved 2 anti-PD1 monoclonal antibodies and multiple additional antibodies are being 
actively investigated in hundreds of clinical trials. PD1 blockade has now been shown to 
generate clinically meaningful tumor regressions in a wide diversity of cancer types, 
13 
 
including advanced and metastatic disease resistant to RT and chemotherapy, with 
durable effects and tolerable toxicity (Chen et al. 2015).  
Combinatorial immune checkpoint blockade 
Despite broad classification as similar agents, therapeutic blockade of CTLA4 and 
PD1/PD-L1 are based on distinct scientific rationale. Summarizing mechanistic work in 
murine models, the major physiologic function of CTLA4 appears to be exerting control 
over T cell responses to self-antigens. Clinical evidence supports this conclusion: 
infiltration of activated T cells occurs both in tumor and normal tissue, often leading to 
broad off-target autoimmunity in multiple major organs such as the skin, gastrointestinal 
track and liver (Weber et al. 2012). Additionally, it remains to be determined how 
important regulatory T cell suppression of endogenous antitumor immune activity is in 
human melanoma or more generally, therefore it appears that anti-CTLA4 primarily 
works by directly removing restraints from largely nonspecific effector T cell reactivity 
(Lühder et al. 1998, Maker et al. 2005, Perrin et al. 1996). In contrast to this, consistent 
with the lack of spontaneous autoimmunity in PD1-deficient mice, (Dong et al. 2004) 
clinical evidence thus far shows a relatively low burden of autoimmunity following 
treatment with anti-PD1/L1 (Arance et al. 2015). This may also be due to the limited 
expression of PD1/L1 during normal homeostasis; in contrast to CTLA4, the PD1 
pathway’s main function appears to be as an inducible regulator at sites of tissue 
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inflammation. Indeed, a recent clinical trial in patients with metastatic melanoma 
comparing anti-CTLA4 and anti-PD1 was stopped ahead of schedule due to superiority 
of the PD1 group with adverse events, as well as superior overall survival (Arance et al. 
2015). Thus, though anti-CTLA4 was initially viewed as the backbone of combinatorial 
immune therapy, this role now belongs to anti-PD1 due in part to its more subtle basic 
immune function and corresponding favorable clinical profile (Mahoney et al. 2015).  
Despite these apparent clinical shortcomings of anti-CTLA4, combinatorial 
immune checkpoint blockade is a critical therapeutic strategy that has resulted in 
improved responses compared to either single modality and is now FDA approved for 
advanced melanoma (Postow et al. 2015a). Only a small subset of patients respond to 
single agent therapy; while improvements in biomarkers may increase response rates due 
to refinements in patient selection, monotherapy is fundamentally limited by the fact that 
mechanisms of immune evasion during the natural history of cancer progression are 
heterogeneous. Many tumor types appear to harbor an indolent endogenous immune 
response, yet different suppressive mechanisms are operative or predominate across 
clinically homogenous patient populations. Resistance pathways to immune therapy are 
similarly diverse. Thus, combinatorial immune therapy in some form is likely to be 
required for durable responses in most patients. Chapter 3 (page 63) reports results of a 
phase I trial evaluating anti-CTLA4 and investigates mechanism of action of dual 
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immune checkpoint blockade with anti-CTLA4 and anti-PD1 in in murine tumor 
models. 
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Agonists of adaptive immunity in cancer 
Effective activation of naïve T cells against tumor cells requires several barriers to 
be overcome that are distinct from those for immune responses against foreign targets. 
First, a high-affinity peptide-MHC interaction must be present, requiring expression by 
tumor cells of genomic regions that are sufficiently non-self that reactive T cells bypass 
mechanisms of central and peripheral tolerance without deletion or anergy. Second, the 
engagement of costimulatory molecules expressed by antigen presenting cells is required. 
Without costimulatory signals, activated naïve T cells undergo apoptosis or transition to 
an anergic state, (Jenkins & Schwartz 1987) an intrinsic immune suppressive mechanism 
that prevents rampant autoimmunity. The canonical costimulatory molecule expressed 
on naïve T cells is CD28, which is required for T cell expansion and effector function. 
However, many other costimulatory molecules exist and contribute to T cell activation 
following antigen encounter, and these molecules have been targeted with monoclonal 
antibodies in the context of checkpoint blockade to augment antitumor responses. This 
strategy has particular relevance in diseases such as pancreatic ductal adenocarcinoma 
where evidence suggests there may be little underlying endogenous antitumor immunity 
in most patients. 
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CD40 
Several therapeutically-leveraged costimulatory molecules are members of the 
tumor necrosis factor superfamily, which were first described as mediators of immune 
response expressed by antigen presenting cells, activated T cells, and activated B cells 
(Moran et al. 2013). CD40 is one such a tumor necrosis factor receptor superfamily 
member and is most notably expressed on dendritic cells (Grewal & Flavell 1998). The 
CD40 ligand CD154 is expressed on activated T cells; ligation of CD40 on dendritic cells 
augments antigen presentation ability and has been shown to be a critical component of T 
cell help (Diehl et al. 1999, French et al. 1999, Sotomayor et al. 1999). Anti-CD40 agonist 
monoclonal antibodies can reverse T cell tolerance in tumor-bearing mice via this 
mechanism, circumventing a potential barrier of CD8 T cell priming by stimulating 
tumor antigen presentation (Bennett et al. 1998, Ridge et al. 1998, Schoenberger et al. 
1998, Wing et al. 2008). CD40 is also expressed by tumor cells in several disease types; 
thus, targeting CD40 may additionally augment antitumor responses by activating 
antibody-dependent cellular cytotoxicity (Li & Ravetch 2011). A further mechanism is 
activation of antitumor macrophages that were capable of mediating T cell-independent 
responses in a murine model of PDA (Beatty et al. 2011).  
Literature shows that anti-CD40 and anti-CTLA4, combined with an ovalbumin 
liposomal peptide vaccine, induce CD8 effector T cells that control ovalbumin-expressing 
leukemia (Ito et al. 2000). Similarly, this combination leads to CD8-dependent complete 
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regression of murine melanoma expressing a highly antigenic, virus-derived protein 
when combined with an adenoviral vaccine directed against this protein (Sorensen et al. 
2010). In phase I clinical trials, anti-CD40 monoclonal antibody was associated with 
immune activity and resulted in partial responses in patients with metastatic melanoma, 
(Bajor et al. 2014, Vonderheide et al. 2001, 2007) and clinical trials investigating the 
combination of anti-CD40 and immune checkpoint blockade are currently underway. 
Radiotherapy 
Increasing evidence suggests that RT can similarly function as an immune agonist, 
augmenting responses to checkpoint blockade or other strategies in tumors with little 
baseline immunity (Demaria et al. 2016). A role for immune cells in RT-induced tumor 
regression was first demonstrated in 1979 (Stone et al. 1979) and later definitively 
confirmed using T cell receptor-transgenic mice (Lee et al. 2009, Lugade et al. 2005). RT 
induces immunogenic cell death, (Apetoh et al. 2007, Golden & Apetoh 2015) responses 
are mediated in part by intratumoral CD8+CD103+ dendritic cells in mice, and responses 
are dependent on the innate DNA damage-sensing cGAS–Stimulator of Interferon Genes 
pathway (Deng et al. 2014b). Crucially, RT has been shown to induce an abscopal effect – 
tumor regression at unirradiated sites such as distant metastases – that depends on CD8 
T cells (Seung et al. 2012) This is likely due to release of tumor antigen and secretion of 
proinflammatory cytokines from irradiated tumor, as shown in the murine B16-F10 
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melanoma model, (Lugade et al. 2005) though the precise mechanisms underlying this 
effect are poorly understood. Local RT in B16-F10 melanoma also promotes regulatory T 
cells, (Lugade et al. 2005) suggesting that anti-CTLA4, which inhibits regulatory T cell 
function, may synergize with RT. Indeed, anti-CTLA4 augments local RT-induced 
abscopal effects on a second, non-irradiated tumor and this effect correlates with CD8 T 
cell tumor infiltration and proinflammatory cytokine production (Dewan et al. 2009). 
Four early case reports showed complete responses to RT + anti-CTLA4 in patients with 
metastatic melanoma, further contributing to excitement (Golden et al. 2013, Hiniker et 
al. 2012, Postow et al. 2012, Stamell et al. 2013). Results from preclinical models also 
support the investigation of combinatorial therapy with RT and anti-PD1 – synergistic 
responses in multiple disease models are mediated by CD8 T cells and correlate with 
decreased markers of immune suppression in the tumor microenvironment (Deng et al. 
2014a, Dovedi et al. 2014, Zeng et al. 2013). Chapter 3 explores this biology, investigating 
the combination of RT and dual immune checkpoint blockade with anti-CTLA4 and 
anti-PD1 in melanoma and pancreatic ductal adenocarcinoma. 
In summary, a broad rationale exists, based on animal models and preliminary 
human data, for combining immune checkpoint blockade with immune agonist strategies 
such as anti-CD40 or RT. This rationale is particularly strong in the case of ‘cold’ tumor 
types with less endogenous immune activity because immune checkpoint blockade 
primarily functions by augmenting pre-existing adaptive immunity. The current 
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challenge is rational selection of combinatorial therapy, especially given that, based on the 
complexity of these immune pathways, mechanisms of action of individual agents may 
differ in combinatorial use. Chapter 3 (page 63) investigates mechanisms and 
determinants RT and CD40 combinatorial therapy with immune checkpoint blockade in 
melanoma and pancreatic ductal adenocarcinoma. 
Melanoma in humans and the B16-F10 murine model  
Melanoma incidence is increasing worldwide and now accounts for 80% of all 
skin cancer deaths, despite representing less than 5% of skin cancer incidence (World 
Health Organization). Accordingly, the prognosis of late stage melanoma remains grim: 
median survival is 6-9 months with chemotherapy despite an excellent survival for local 
disease of greater than 95% (Garbe et al. 2011). Prognosis of advanced disease varies 
based on extent of dissemination, such as the presence of visceral disease or brain 
metastases (Bedikian et al. 2009). These statistics reflect the underling reality that 
melanoma is highly chemotherapy resistant; the wide range of treatments to which 
melanoma is refractory further suggests that underlying mechanisms of resistance are 
complex, seemingly linked as much to the intrinsic biology of melanocytes as to acquired 
therapeutic resistance (Soengas & Lowe 2003).  
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Prior to immune checkpoint blockade, the only FDA-approved therapy for 
metastatic melanoma was dacarbazine, hydroxyurea and interleukin-2, none of which 
were tested in large, randomized clinical trials, and standard of care was enrollment in 
experimental therapy. In 2006, a fully-human anti-CTLA4 monoclonal antibody was 
shown to have mild toxicity, a 7% complete response rate, and long-term durable 
responses in an initial phase I dose escalation study (Gomez-Navarro et al. 2006). This 
result was subsequently confirmed in a landmark 2010 phase III study, (Hodi et al. 2010) 
resulting in anti-CTLA4 becoming the first drug to receive FDA approval for the 
treatment of metastatic cancer. Anti-PD1, the most promising second generation 
immune checkpoint antibody, has also shown promising results in patients with 
metastatic melanoma based on initial studies demonstrating objective response rates in a 
quarter of patients (Hamid et al. 2013). Furthermore, an expansion cohort trial of 173 
patients with anti-CTLA-refractory disease demonstrated improvements in overall 
response with anti-PD1 treatment, and subsequent randomized phase II and III studies 
has established anti-PD1 as effective in this patient subpopulation (Ribas & Flaherty 
2015). Thus, it has been difficult in recent years to overstate the perceived promise of 
immune checkpoint blockade to change clinical management of advanced melanoma. 
Melanoma is an ideal model to study CD8 effector T cell resistance mechanisms 
because endogenous antitumor immunity in melanoma is clearly mediated by this cell 
population (Erdag et al. 2012, van Houdt et al. 2008). Infiltrating immune cells were first 
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described in cutaneous melanoma, in one of the first such discoveries in any tumor type, 
by Clark and Mihn in 1969, (Clark et al. 1969), and many years passed before these cells 
were subsequently shown to correlate with overall survival (Day et al. 1981, Tuthill et al. 
2002). Syngeneic murine melanoma models have been a cornerstone for mechanistic 
investigations of tumor-immune interactions. The most widely used murine melanoma 
model, and likely the most widely used murine cancer model, is the B16 cell line (Kuzu et 
al. 2015). B16-F10 is an established sub-clone with high metastatic potential, rapid 
dissemination of metastatic disease, (Herlyn & Fukunaga-Kalabis 2010) and relatively 
poor endogenous immunogenicity due in part to low levels of MHC class I expression 
(Becker et al. 2010). B16-F10 shares characteristics with human melanoma, including 
inactivating mutations in Cdkn2a. Indeed, compared with initial murine studies showing 
efficacy of single agent anti-CTLA4, (Leach et al. 1996) B16-F10 does not respond to 
single agent CTLA4; instead, anti-CTLA4 must be combined with other agents thought to 
stimulate endogenous antitumor T cell response such as granulocyte-macrophage colony-
stimulating factor (van Elsas et al. 1999). Similarly, anti-PD1 combined with RT, but not 
either modality alone, induces antitumor T cell responses in this model against tumor-
specific antigens (Sharabi et al. 2015). In summary, B16-F10 is a useful murine model for 
combinatorial immune therapy due to its verisimilitude to human melanoma resistance 
to adaptive immunity. An additional advantage is rapid cell proliferation that permits 
multiple in vivo passages, further facilitating this study of resistance mechanisms. 
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New clinical trials in patients with metastatic melanoma focus on investigating 
potential advantages of combinatorial immune therapy with radiation or chemotherapy. 
The critical outstanding scientific objectives, with multiple immunotherapeutic agents 
approved or emerging, is to develop biomarkers and rational strategies for combination 
therapy. 
Pancreatic adenocarcinoma in humans and the KrasG12D; p53fl/+; Pdx1-Cre murine model  
Pancreatic ductal adenocarcinoma (PDA) is a nearly universally lethal form of 
cancer, with an 5-year survival rate that remains below 5% despite decades of attempts at 
improvement (Hidalgo 2010). It is the third most common cause of cancer death and 
PDA incidence appears to be increasing – PDA will overtake colorectal adenocarcinoma 
to become the second most common cause of cancer death by 2030 (Rahib et al. 2014). 
PDA lethality is due in part to the anatomical location of the pancreas, which allows for 
long periods with few specific clinical manifestations, such that more than 80% of 
patients have advanced disease at the time of diagnosis (Hidalgo 2010). New 
combinatorial chemotherapy strategies in PDA have resulted in minimal impact on 
patient outcomes; though these recent strategies have modest response rates of 20-30%, 
there has been little change in rates of durable response (Conroy et al. 2011, Hoff et al. 
2013). Immune therapy, having demonstrated profound potential for impact on response 
rates in other disease types, has thus been a strategy of great promise in PDA (Foley et al. 
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2015, Vonderheide & Bayne 2013). Furthermore, exciting preliminary studies have 
suggested that a small subset of PDA tumors have a relatively immunogenic profile, 
characterized by greater infiltration of T cells and prominent proinflammatory signal, 
(Bailey et al. 2016a, Fukunaga et al. 2004) and survival of PDA patients whose tumors are 
resectable appears to correlate positively with T cell infiltration (Fukunaga et al. 2004, 
Hiraoka et al. 2015, Ino et al. 2013). Despite this rationale and myriad successes in other 
disease types, immune-modulating strategies such as anti-PD1/PD-L1 and anti-CTLA4 
have thus far uniformly failed to show efficacy in more than a very small proportion of 
patients with PDA (Brahmer et al. 2012, Royal et al. 2010). This is perhaps due to the fact 
that hallmarks of PDA in the majority of patients are a predominant desmoplastic 
stroma, (Vonderheide & Bayne 2013, Wörmann et al. 2013) essentially no T cell 
infiltration in most cases, and prominent upregulation of immune suppressive pathways 
(Bailey et al. 2016b, Beatty et al. 2011). This clinical reality demands deeper mechanistic 
understanding of determinants of immune activity in PDA, which is explored in both 
chapters 3 (page 63) and 4 (page 103). 
PDA develops from pancreatic intraepithelial neoplasia in linear fashion, with 
each progressive stage typified by a greater load of genetic abnormalities in common 
oncogenic driver and tumor suppressor genes (Rahib et al. 2014). Aspects of PDA 
oncogenesis are incompletely understood – other pancreatic lesions such as intraductal 
papillary mucinous neoplasia can also generate PDA, (Kopp et al. 2012) and recent 
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evidence indicates that PDA oncogenesis may sometimes be an abbreviated, catastrophic 
process (Notta et al. 2016). Regardless of etiology, the genetic hallmark of PDA is a 
dominate mutation in the KRAS2 oncogene leading to constitutive activation of the 
canonical downstream MAPK/ERK pathway. Progression from pancreatic intraepithelial 
neoplasia is also associated with increasingly frequent mutations in p16INK4a, p53, 
DPC4/SMAD4, and BRCA2 (Hruban et al. 2000).  
The high prevalence and recognized importance of mutations in KRAS2 led to 
development of a murine PDA model using targeted endogenous expression of KrasG12D, 
the most common KRAS2 activating mutation. Expression is restricted to presumed 
progenitor cells using Cre-lox recombination tied to the pancreatic-specific promoters 
p48 or Pdx1 (Hingorani et al. 2003). These mice recapitulate with high fidelity the 
progression from pancreatic intraepithelial neoplasia to PDA; spontaneous evolution 
occurs as mice age with eventual invasive primary lesions and metastatic disease. The 
addition of a second hallmark PDA genetic lesion with restricted pancreatic expression, 
TP53R172H (a dominant-negative TP53 isoform similar to that found in Li-Fraumeni 
syndrome), resulted in a murine PDA model (KPC, KrasLSL-G12D/+;p53LSL-R172H/+;Pdx-1-Cre) 
with 100% penetrance within 6 months of birth (Clark et al. 2009, Hingorani et al. 2005). 
Furthermore, the KPC model recapitulates the dense desmoplastic stroma, prominent 
immune suppressive pathways, and absence of CD8 T cell infiltrate that characterizes the 
majority of human PDA tumors (Beatty et al. 2011, Clark et al. 2007). Myeloid-derived 
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suppressor cells, which limit CD8 effector T cell function through secretion of arginase 
and inducible nitric oxide synthase, and other tumor-associated macrophages 
characterized by secretion of suppressive cytokines IL-10 and IL-6, are hallmarks of the 
KPC immune microenvironment (Bayne et al. 2012, Beatty et al. 2011, Clark et al. 2007, 
Gabrilovich et al. 2012).  
This presence of immune suppressive pathways and lack of endogenous CD8 T 
cell infiltration suggest that the PDA tumor microenvironment may be a site of acquired 
immune privilege, in contrast to other tumor types such as melanoma in which 
endogenous T cell activity may itself drive immune suppression (Spranger et al. 2013). In 
this context, acquired immune privilege is defined as a state of suppressed lymphocyte 
responses to antigens that is actively and locally enforced, and is distinct from central 
tolerance (Mellor & Munn 2008). The canonical example of this biology is the immune 
homeostasis present at large mucosal surfaces where the risk of immune activation 
against benign foreign antigens is omnipresent. In the context of cancer, this hypothesis 
suggests that PDA tumors may be therapeutically susceptible to T cell-mediated 
destruction provided T cell infiltration and activation can be sufficiently augmented. In 
other words, paradoxically, the lack of baseline T cell infiltration in PDA may result in a 
tumor microenvironment that does not strictly adhere to the immune editing hypothesis. 
In PDA, no or minimal selective immune pressure may result in clinically-detectable 
tumors of high potential, if not apparent, antigenicity. Indeed, increasing data from 
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mouse models suggest that T cell responses against KPC tumors can be strikingly robust, 
and even curative, when immune suppressive pathways are inhibited or antigenicity is 
sufficiently strong (Byrne & Vonderheide 2016, Winograd et al. 2015). In particular, 
recent data demonstrate that combinatorial treatment with anti-CD40 and chemotherapy 
can overcome baseline refractoriness to immune checkpoint blockade (Winograd et al. 
2015).  
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Targeting of tumors cells by CD8 T cells 
The ability of checkpoint blockade to induce durable responses in an increasing 
range of malignancies creates an urgent need to understand why the majority of tumors 
across disease types are either not responsive or develop resistance to T cell-mediated 
immunity.(Sharma & Allison 2015) Many efforts to identify predictive biomarkers of 
checkpoint blockade have identified immune and tumor pathways of importance; (Herbst 
et al. 2014, Taube et al. 2014, Topalian et al. 2015, Tumeh et al. 2014) however, there 
remains a need for immune dynamics across human tumor types to be extensively 
characterized. 
Tumor antigens targeted by T cells 
The etiology of antigens targeted by antitumor T cell responses is one such 
inadequately explored area. In vitro expression library screening of tumor-infiltrating 
lymphocytes was the initial method of identifying tumor antigens. In these experiments, 
PBMCs were sensitized against autologous tumor or normal cells pulsed or transfected 
with potential tumor epitopes. Five classes of antigens emerged from these studies: viral 
antigens, over-expressed gene projects, tissue-specific differentiation antigens, cancer 
germline antigens, and mutated antigens, also called neoepitopes (Lu & Robbins 2015). 
Availability of viral antigens as targets for T cells, such as HPV E6 and HPV E7, is limited 
29 
 
to specific tumor types such as cervical and head and neck cancers. Furthermore, immune 
responses can be limited by viral immune evasion mechanisms, perhaps contributing to 
the fact that targeting these antigens is effective at preventing disease but does not 
produce clinically meaningful antitumor responses in patients whose disease has 
progressed (van Poelgeest et al. 2013). Over-expressed gene products, such as PRAME, 
(Epping & Bernards 2006) are enticing targets due to their wide expression across tumor 
types. However, this class of antigens is also expressed at nominal levels in normal tissue, 
and responses are likely to generate either peripheral tolerance or, if this tolerance is 
broken, autoimmunity. Tissue-specific differentiation antigens and cancer germline 
antigens are expressed less widely, restricted to a single tissue of origin or germ cells, 
respectively, but nevertheless may have the same fundamental limitation. Germ cells lack 
expression of MHC, reducing risk of autoimmunity, and clinical trials evaluating 
adoptive transfer of the cancer germline antigen NY-ESO-1 have achieved objective 
responses in more than 50% of selected patients with myeloma and melanoma (Rapoport 
et al. 2015, Robbins et al. 2015). Yet the relatively small number of these antigens that 
have been identified – and a lack of truly robust endogenous responses in most cases – 
has motivated efforts to identify tumor-specific peptides capable of generating immunity. 
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Neoepitopes in cancer immunotherapy 
Increasing evidence indicates that neoepitopes, antigens derived from somatic 
mutations and seen as foreign by the immune system, are critical mediators of tumor 
immunity (Schumacher & Hacohen 2016). Targeting neoepitopes has, by definition, the 
theoretical advantage of bypassing both immune-intrinsic suppressive mechanisms as 
well as the threat of autoimmunity. Furthermore, though precise antigens likely differ 
across patients, this class of antigens is a tractable target in virtually all forms of cancer 
with more than a handful of genetic abnormalities that generate non-self-peptides that 
can be presented on MHC. For these reasons, investigating the determinants of immune 
responses against neoepitopes has generated tremendous interest. Higher predicted 
neoepitope load is associated with baseline lymphocyte infiltration and survival in 
colorectal tumors in the absence of immunotherapy. (Giannakis et al. 2016) 
Therapeutically, degree of DNA damage is associated with improved response to anti-
CTLA4, (Snyder et al. 2014) and responses to anti-PD1 in patients with NSCLC also 
correlate with neoepitope load (Rizvi et al. 2015). Similarly, a strong correlation exists 
between mismatch repair deficiency and response to anti-PD1 (Le et al. 2015) and 
between mutation or MHC class I neoepitope load and response in melanoma or 
urothelial carcinoma, respectively (Hugo et al. 2016, Rosenberg et al. 2016). A recent 
analysis of whole exome sequencing from patients with metastatic melanoma identified 
neoepitopes recognized by adoptively-transferred tumor-infiltrating lymphocytes, and 
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neoepitope load was associated with objective tumor regressions (Robbins et al. 2013). 
Taken together, this preponderance of recent findings suggests neoepitopes can drive 
productive antitumor responses in humans and may be predominant targets of these 
responses.  
Studies in mice and humans have suggested that neoepitopes derived from 
mutant Kras can serve as tumor rejection antigens, (Fossum et al. 1995, van Elsas et al. 
1995) and this was recently demonstrated to be the case in a patient treated with 
adoptively-transferred autologous T cells specific for mutant KrasG12D (Tran et al. 2016). 
KrasG12D-specific T cells made up 75% of adoptive-transferred cells and mediated 
objective regression of 100% of lung metastases. A single lesion that progressed after 9 
months was found to have lost the crucial HLA allele required for KRAS activity. This 
unusual case report is direct, albeit anecdotal, evidence of neoepitope-directed antitumor 
responses in a therapeutic setting. 
 Murine models have provided further mechanistic support for the hypothesis that 
neoepitopes are predominant tumor rejection antigens, including the hallmark study 
from Robert Schreiber et al. supporting the cancer immunoediting hypothesis, which 
demonstrated that a point mutation in Spectrin-beta2 could drive tumor rejection 
(Matsushita et al. 2012). In B16-F10 melanoma, 11 of 50 mutated peptides identified on 
the basis of predicted affinity for MHC class I from whole exome sequencing 
preferentially induced immune responses (Castle et al. 2012). Therapeutically, 
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immunization of mice against MHC class I or II neoepitopes resulted in slowed tumor 
growth and enhanced survival (Kreiter et al. 2015, Yadav et al. 2014). In summary, 
correlative studies suggest that neoepitopes may be primary targets in the context of 
immune checkpoint blockade, and that these immune targets can mediate tumor 
regression in mice and humans. 
Cancer immunotherapy neoepitope prediction 
The emerging importance of neoepitopes in antitumor responses necessitates the 
ability to understand determinants of T cell immunity to this class of antigens. Tumor 
DNA and RNA sequencing provide a vast landscape of tumor-specific gene expression 
and mutations that can be used to identify MHC class I and II neoepitopes. 
Computational neoepitope prediction using these genomic data is a complex problem, in 
large part due to the MHC restriction of antigen presentation. Murine and human cells 
express 6 MHC class I molecules and antigen presenting cells express 8 or more MHC 
class II molecules. Determinants of preferential binding differ substantially across MHC 
type, allele, and peptide length, and more than 3000 HLA alleles exist (Leone et al. 2013). 
Furthermore, expression of mutant proteins – as well as processing and presentation of 
peptides – differs substantially within and across tumors. This vast diversity requires that 
the ability of a mutated peptide to function as a neoepitope is assessed at the level of 
individual tumor samples. 
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High throughout computational pipelines to mine tumor mutations, expression 
levels, and MHC types have arisen to meet this need.(Gfeller et al. 2016) These analyses 
generally begin with whole exome sequencing of tumor and normal tissue to identify 
somatic variants present only in tumor tissue, which can be readily identified with high 
accuracy if coverage depth is sufficient (Sims et al. 2014). Ideally, matched RNA 
sequencing is then used to identify genes at least minimally expressed in tumors and 
therefore capable of being processed and presented in the context of MHC. RNA 
sequencing additionally allows for identification of cancer-specific splice variants and 
gene fusions that can also result in novel peptides. 
Predicting neoepitopes that drive T cell responses with high specificity and 
sensitivity, particularly those that are good vaccine candidates, has been enormously 
challenging (Gfeller et al. 2016). Several high throughout pipeline components for 
increasingly accurate identification of MHC alleles, DNA variant candidates, expressed 
genes, and high-affinity peptides have been developed to meet this demand. To generate 
effector T cells, a genetic variant must result in peptide fragments of 8-14 amino acids 
that bind specific MHC with high enough affinity to persist stably in the MHC binding 
groove for presentation. Peptide N- and C- terminal residues are generally involved in 
binding MHC and are therefore critical for this stability, and evidence suggests that 
higher affinity interactions between peptide and MHC may preferentially result in 
epitopes capable of stimulating T cells (Leone et al. 2013). Based on these rules, predictive 
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computational methods have been developed to align peptides and, using large sets of 
training data, infer novel peptide affinity for MHC according to the presence or absence 
of conserved motifs (Falk et al. 1991). The most accurate of these methods use machine 
learning approaches such as neural networks, hidden Markov models or support vector 
machines capable of considering complex sequence patterns as high-dimensional 
problems (Dönnes & Elofsson 2002, Nielsen & Lund 2009). Across most HLA types, as 
shown to be the case for diverse algorithms designed to replicate biological processes, 
consensus methods combining methodologically orthogonal approaches have yielded the 
best results (Vita et al. 2015). Various downstream steps have been investigated to 
improve peptide predictions, such as consideration of peptide cleavage site preference, 
complex peptide-MHC structures, or peptide transport predictions, (Antes et al. 2006, 
Larsen et al. 2005, Nielsen et al. 2005) but it is not yet clear if these computationally-
intensive added steps lead to improved predictions. 
 CD4 T cells are a major component of tumor-infiltrating lymphocytes and have 
been shown to mediate tumor regression independent of CD8 T cells in murine models of 
adenocarcinoma (Kreiter et al. 2015, Tran et al. 2014). Consequently, computational 
methods for predicting MHC class II affinity may also be useful for modeling antitumor 
responses. The relatively laxity of peptide interactions with MHC class II make these 
predictions more challenging; experimental evidence indicates that a greater diversity of 
peptide lengths are able to stably interact with MHC class II and, in the case of HLA-DR, 
35 
 
polymorphic alpha and beta chains reduce the ability of algorithms to extrapolate from 
conserved binding rules based on peptide motifs. For both MHC class I and class II 
predictions, a minority of predicted high-affinity peptides generate T cell reactivity in 
animal models or patients, (McGranahan et al. 2016) yet computational neoepitope 
prediction does substantially enrich for reactive peptides (Castle et al. 2012).  
The multiple order of magnitude decrease in the cost of genomic sequencing over 
the past 20 years has enabled cancer sequencing efforts that can now be used to 
investigate tumor antigens across human cancer (Hayden 2014). The Cancer Genome 
Atlas (TCGA), now Genome Data Commons, provides a large, multidimensional set of 
genome-wide sequencing ideally suited for investigating pan-cancer and disease-level 
interactions between genetic and immune factors. TCGA includes paired normal and 
tumor exome sequencing required for somatic variant identification and HLA-typing, as 
well as RNA sequencing required for determining variant expression and inferring tumor 
microenvironment immune activity. Previous work using the first subset of TCGA 
disease types available showed that predicted MHC class I neoepitopes correlate with 
patient survival across colorectal adenocarcinoma, ovarian serous cystadenocarcinoma, 
breast carcinoma, glioblastoma, kidney renal clear cell carcinoma, and lung 
adenocarcinoma, (Brown et al. 2014) and that MHC class I neoepitopes correlate with 
cytolytic immune activity in lung and stomach adenocarcinoma, head and neck 
squamous cell carcinoma, uterine carcinosarcoma and thyroid carcinoma (Rooney et al. 
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2015). Beyond these initial compelling studies, the broad landscape of interactions 
between neoepitope load and immune dynamics in the tumor microenvironment 
remains inadequately explored.
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CHAPTER 2 – Materials and methods 
Clinical trial patients and study design 
A clinical protocol of ipilumimab (anti-CTLA4) and RT for patients with met 
melanoma was registered on clinicaltrials.gov (NCT01497808). Eligible patients were at 
least 18 years of age with previously treated or untreated stage IV melanoma with 
multiple metastasis. Patients were required to have an Eastern Cooperative Oncology 
Group performance status of 0 or 1, adequate renal, hepatic, and hematological function, 
no current or history of CNS metastasis, no prior radiation that precludes use of 
stereotactic body radiation (SBRT), and at least one tumor between 1-5 cm that could be 
treated with SBRT. The primary objectives of this phase I study were to determine 
feasibility, dose-limiting toxicities (DLT) and maximum tolerated SBRT fraction when 
given in conjunction with ipilimumab. The secondary objectives were to determine late 
toxicity, immune-related clinical responses and changes. The study treated successive 
cohorts of patients with escalating doses of SBRT to a single tumor (index lesion), 
followed 3-5 days later by ipilimumab every three weeks for four doses. Moderate RT 
doses were used since higher RT dose has not been clearly correlated with better immune 
response but would likely increase toxicity. Patients were stratified into two stratum based 
on treatment site (lung or bone vs. liver or subcutaneous) and dose escalation of SBRT 
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were determined as follows: For lung/bone lesion, dose level 1 (DL1) was 8 Gy x 2; dose 
level 2 (DL2) was 8 Gy x 3; and for liver/subcutaneous lesion, DL1 was 6 Gy x 2; DL2 was 
6 Gy x 3. The study followed a “treat six” design with the goal of accruing 6 patients to 
each dose level, or 24 patients total. Enrollment to a dose level would stop if 2 or more 
patients had a DLT. If 0-1 patients out of the 6 had a DLT at DL1, escalation to DL2 
would proceed. No DLTs were observed, defined by the protocol as any treatment-related 
grade 4 or higher immune-related toxicity (NCI CTC Version 4.0) or grade 3 or higher 
non-immune related toxicity experienced during study treatment or within 30 days after 
the last injection of ipilimumab. Pre- and post-treatment blood, CT, and PET/CT were 
obtained to follow tumor response and assess immune responses. Response evaluation by 
imaging was performed within 60 days of the last ipilimumab treatment using either 
RECIST v1.1 (Eisenhauer et al. 2009) or PERCIST. The study protocol was approved by 
the University of Pennsylvania institutional review board. All participating patients 
provided written informed consent. 
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Murine studies 
Cell lines and tissue culture 
B16-F10 was purchased from ATCC. TSA was a gift from Sandra Demaria. 
PDA.4662 cell line was derived from single cell suspensions of PDA tissue from LSL-
KrasLSL-G12D/+,LSL-p53LSL-R172H/+,Pdx1-Cre mice as previously described (Bayne et al. 2012). 
B16-F10 and PDA.4662 cell lines were cultured at 37º C in DMEM and TSA cells were 
cultured at 37º C in RPMI. Media was supplemented with 10% FBS, 100 U/ml penicillin 
and 100 ug/ml streptomycin, 2 mM L-glutamine. All cell lines were determined to be free 
of Mycoplasma (Lonza) and common mouse pathogens (IDEXX).  
In vivo tumor growth experiments 
Five- to seven-week-old female C57BL/6 and BALB/c mice were obtained from 
NCI Production (Frederick, MD) and Jackson Laboratory (Bar Harbor, ME) and 
maintained under pathogen free conditions. All animal experiments were performed 
according to protocols approved by the Institute of Animal Care and Use Committee of 
the University of Pennsylvania. For B16-F10 melanoma, 5x104 B16-F10 cells were mixed 
with an equal volume of Matrigel (BD Biosciences) and subcutaneously injected on the 
right flank of C57BL/6 mice on day 0 and the left flank on day 2. The right flank tumor 
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site was irradiated with 20 Gy on day 8. Blocking antibodies were given on days 5, 8 and 
11. For the concurrent vs. sequential RT experiment, the right flank was irradiated on 
either day 8 (sequential) or 12 (concurrent), while blocking antibodies were given on days 
9, 12, and 15. For TSA breast cancer, 1x105 TSA cells were mixed with an equal volume of 
Matrigel (BD Biosciences) and subcutaneously injected on the right flank of BALB/c on 
day 0 and the left flank on day 2. The right flank of the mice was irradiated with 8 Gy on 
three consecutive days starting on day 10 or 11 post tumor implantation. Blocking 
antibodies were started 3 days prior to RT and given every 3 days for a total of 3 doses. 
For the pancreatic cancer model, 4x105 PDA.4662 cells were subcutaneously injected on 
the right flank. The right flank was irradiated with 20 Gy on day 8. Blocking antibodies 
were given on days 5, 8, and 11. For melanoma and breast cancer models, I used the 
optimal dose and fraction of radiation as previously reported (Dewan et al. 2009, Lee et al. 
2009). All irradiation was performed using the Small Animal Radiation Research 
Platform (SARRP). Antibodies used for in vivo immune checkpoint blockade experiments 
were given intraperitoneally at a dose of 200 µg/mouse and include: CTLA4 (9H10), PD1 
(RMP1-14), PDL-1 (10F.9G2), CD8 (2.43), and rat IgG2B isotype (LTF-2) (BioXCell). 
CD40 (BioXCell) was given at a dose of 100 µg/mouse on day 11 only based on prior 
studies showing this dose to have equivalent pharmacodynamic effect to higher doses in 
mice and humans (Beatty et al. 2011, Kedl et al. 2001, Vonderheide et al. 2007). Anti-CD8 
was given 2 days prior to tumor implantations (day -2), day 0, then every 4 days for the 
duration of the experiment. Perpendicular tumor diameters were measured using 
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calipers. Volume was calculated using the formula L x W2 x 0.52, where L is the longest 
dimension and W is the perpendicular dimension. 
Survival and tumor response analysis 
Differences in survival were determined for each group by the Kaplan-Meier 
method and the overall p-value was calculated by the log-rank test using the “survival” R 
package version 2.37+. For mouse studies, an event was defined as death or when tumor 
burden reached a protocol-specified size of 1.5 cm in maximum dimension to minimize 
morbidity. To help control for differences in treatment response due to experimental 
variation or intrinsic growth differences with sublines, tumor volume measurements were 
also analyzed after normalizing to the average volumes of untreated control mice. These 
average untreated tumor volumes were determined at day 11-12, a time when tumor 
dimensions could be accurately measured, and was considered a baseline tumor volume 
(Vcont). Normalized tumor response to treatment is the measured volume (V) relative to 
Vcont, or V/Vcont, a dimensionless value that is relative to a baseline volume. 
Measurements from different experiments separated by 1-2 days were binned. 
Differences in growth curves were determined by a mixed effect linear model with 
normalized data using the “lmerTest” R package version 2.0. Sample size estimations were 
based on preliminary pilot experiments. For control mice, I expected an average tumor 
volume of 0.4 cm3 at day 17-21. For most experiments, I assumed the treatment group 
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would have an effect size resulting in a 50% reduction in average tumor volume. Sigma 
was estimated to be 1.5. For a 0.80 power at the 0.05 alpha level, this gave us a sample size 
of 5 mice. Mice were randomly assigned a treatment group. For experiments whereby the 
effect size was expected to be small and/or non-robust, two independent researchers with 
at least one researcher blinded to the treatment group assignments performed caliper 
measurements. 
Flow cytometry 
For flow cytometric analysis of in vivo experiments, blood, spleen, and tumor 
were harvested at either day 16 or 18 post tumor implantation. Single cell suspensions 
were prepared and red blood cells were lysed using ACK Lysis Buffer (Life Technologies). 
Live/dead cell discrimination was performed using Live/Dead Fixable Aqua Dead Cell 
Stain Kit (Life Technologies) or Sytox Red Dead Cell Stain (Life Technologies). Cell 
surface staining was done for 20-30 minutes. Intracellular staining was done using a 
fixation/permeabilization kit (00-5521-00, eBioscience.) T effector cells were phenotyped 
as CD8+CD44+, myeloid derived suppressor cells (MDSC) as CD11b+Gr-1+, and 
regulatory T cells as CD4+FOXP3+. All flow cytometric analysis was done using an LSR II 
(BD) or FACSCalibur (BD) and analyzed using FlowJo software (TreeStar) or the 
FlowCore package in the R language and environment for statistical computing. 
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CRISPR gene targeting 
Gene targeting by CRISPR/Cas9 was accomplished by co-transfection of a Cas9 
plasmid (Addgene, 56503), the guide sequence (selected using ZiFit Targeter) cloned into 
the gBlock plasmid, and a plasmid with the puromycin selection marker. Successful 
targeting of PD-L1 was determined by flow cytometry screening of clones treated with 
and without 100 ng/mL of interferon-γ (PeproTech). Confirmed clones were pooled. 
Clones without knockout were also pooled and used as controls.  
Immunohistochemistry for PD-L1 
Formalin-fixed, paraffin-embedded tumors were collected at the time of surgical 
resection or from biopsy. All patients with available recent biopsy, which was optional for 
trial enrollment, were used for analysis. After heat-induced antigen retrieval (Bond ER2, 
20 min.), the tumor slides were stained with an anti-PD-L1 antibody (E1L3N, Cell 
Signaling) at 1:50 dilution. Intensity of staining on a 0-3+ scale, the percent tumor cells or 
macrophages with positive staining, and the cellular pattern (membrane vs. cytoplasm) 
were analyzed by two pathologists. Samples with membrane PD-L1 staining intensity 
score of 0-1 were classified as PD-L1lo, and samples with an intensity score of 2+ in at 
least 1% of the cells were classified as PD-L1hi. To confirm specificity, the anti-PD-L1 
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antibody was validated by staining Hodgkin’s lymphoma cells (Green et al. 2010) and 
placenta (Holets 2006).  
Microarray data processing and normalization 
Total RNA was isolated and purified from cells using Isol-RNA Lysis Reagent 
(Fisher.) Total RNA from tumors was isolated and purified from frozen specimens using 
Isol-RNA Lysis Reagent and Qiagen RNAeasy extraction kit with DNAase I on column 
treatment. Labeled RNA was hybridized to the Affymetrix GeneChip Mouse Gene 1.0 and 
2.0 ST Array. Affymetrix CEL files for all samples were processed using the RMA method 
as implemented in the “oligo” R package version 1.26.6. Probe annotations were provided 
by the “mogene10sttranscriptcluster.db” and “mogene20sttranscriptcluster.db” R package 
version 8.0.1 and 2.13.0, respectively. Since different array types and different batches 
were used, each expression set was z-score transformed (Cheadle et al. 2003) and median 
centered. Multiple probes for the same gene were averaged and only genes common to 
the 1.0 and 2.0 ST arrays were kept. Batch effects were adjusted using the ComBat method 
as implemented in the “sva” R package version 3.8.0. The microarray data has been 
deposited at the GEO (GSE65503). Gene expression data for primary melanoma samples 
were downloaded from the GEO (GSE22155). For this data set, the post-processed data 
and provided annotations were used. 
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Determining differentially expressed genes and enriched gene sets 
Non-specific filtering was used to remove genes with an interquartile range less 
than 0.05. To find differentially expressed genes (DEGs) between parental sensitive and 
resistant tumors, Significance Analysis of Microarray (Tusher et al. 2001) (“samr” R 
package version 2.0) was applied using a two class unpaired comparison, minimal fold 
change of 1.2, and median false discovery rate (FDR) of 0.05. Unannotated transcripts 
were not considered. To test whether gene sets were enriched in response to different 
conditions, we utilized Gene Set Analysis as implemented in the “GSA” R package version 
1.03 (Efron & Tibshirani 2007). The “maxmean” test statistic was used to test enrichment 
using a two-class comparison. All p-values and false discovery rates were based on 500-
1000 permutations. For restandardization, a method that combines randomization and 
permutation to correct permutation values of the test statistic and to take into account the 
overall distribution of individual test statistics, the entire data set was used rather than 
only the genes in the gene sets tested. 
Flow cytometry data processing 
Gating was performed using either FlowJo version 9.7.5 or the FlowCore R 
package version 1.28.24. For computational modeling, values were normalized by 
subtracting the average values of untreated controls. For the CD8/Treg ratio, the percent 
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CD8+CD44+ cells were divided by the percent CD4+FOXP3+ cells. Because these data 
could be skewed with varying and wide distributions, these data were log transformed for 
downstream analysis. 
TCR deep sequencing and clonotype diversity analysis 
DNA from pre-treatment blood, post-treatment blood, and tumor was extracted 
on day 16 using the Qiagen DNA extraction protocol. Samples were sequenced by 
Adaptive Biotechnologies using “survey” sequencing depth for tumor and “deep” 
sequencing depth for blood samples. Processed data were downloaded and 
frequencies/counts for TCR clonotypes were examined by nucleotide sequences after 
non-productive reads were filtered out. The top 100 most frequent TCR clonotypes in the 
tumor were used to examine their frequencies in the pre- and post-treatment blood. The 
Shannon’s diversity index (Rempala & Seweryn 2012) (DI) normalized to the number of 
reads (DI = -å (pi ln pi) / ln n, where n is the number of clones, pi is the clonal frequency 
of the ith clone, and sigma is summed from i=1 to i=n) was calculated for each sample. 
This gives a value between 0 and 1, where 0 is monoclonal and 1 is an even distribution of 
different clones.  
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Unsupervised and supervised analysis of CDR3 amino acid properties 
Based on previously described methods (Atchley et al. 2005, Thomas et al. 2014), 
Atchley factors were used to reduce a linear sequence of amino acids into analyzable 
numeric features of distinct amino acid properties. The five Atchley factors and the 
attributes they measure are: 1) PAH: accessibility, polarity, and hydrophobicity, 2) PSS: 
propensity for secondary structure, 3) MS: molecular size, 4) CC: codon composition, 5) 
EC: electrostatic charge. Each CDR3 was represented as a set of all possible contiguous 
amino acids of length p (p-tuple). p=3 was chosen based on previous published reports 
but examined a range of p values, which gave comparable results (see below). For each p-
tuple, the Atchley factors for the amino acids were then calculated to give a vector of 
length 5p, or 15 (3 amino acids x 5 Atchley factors). Thus, each CDR3 was represented by 
a set of these vectors. The average values for these vectors were calculated for the top B 
most frequent clones from the post-treatment blood. A cut-off of B=5 was chosen based 
on examination of the frequency distribution of the TCR clonotypes and an estimate of 
the number of clones with extreme values compared to the rest of the distribution. These 
averaged values were then clustered into two groups by k-means clustering with k=2. The 
association between cluster membership and treatment with or without RT was 
calculated by Fisher’s exact test. This entire process was repeated for the five clones in the 
pre-treatment blood, for randomly drawn clones from the post-treatment blood, for p-
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tuple lengths from p=2 to 10, and for cut-off values from B=3 to 50. In all cases, the 
distribution of p-values was compared to the p-value from the observed data.  
Although averaging the Atchley factor values is a simple method to agglomerate 
CDR3 features for unsupervised classification, it does not provide insight into how 
treatment groups influence the amino acids that comprise the CDR3. To understand 
which sets of p-tuples were most strongly influenced by treatment groups with RT, 
without RT, and pre-treatment blood, this work used previously described methods 
(Thomas et al. 2014) to assign p-tuples into n clusters based on their Atchley factor 
vector. Model based clustering with cluster number determination using the “mclust” R 
package was applied to all p-tuples from the top five clones in all treatment groups from 
pre- and post-treatment blood. This gave rise to 17 clusters, or subsets, of p-tuples. The 
proportion of p-tuples belonging to each of these 17 subsets, denoted Pi, was then 
calculated for each clonotype and used as features. The subsets that were most influenced 
by treatment group (treatment group with RT, without RT, or pre-treatment) were then 
analyzed by multivariable RF regression using a design matrix for treatment groups as the 
x-variable and Pi as the response variable. The variables Pi most affected by each 
treatment group were selected by comparing the observed importance scores to the 
importance scores generated by permutation. To determine the location and frequencies 
of amino acids belonging to the selected p-tuple subsets across the variable length CDR3 
region, the CDR3 of each clone was divided into 10 bins of equal size. Then, the 
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proportion of p-tuples in each of these 10 bins belonging to the selected subset was 
calculated and compared between treatment groups. 
Guide RNA sequences 
Gene block contains 20 bp target size (N), U6 promoter, gRNA scaffold, and 
termination signal. The sequence and sequences for each guide used are as follows: 
TGTACAAAAAAGCAGGCTTTAAAGGAACCAATTCAGTCGACTGGATCC
GGTACCAAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCTTCATATTT
GCATATACGATACAAGGCTGTTAGAGAGATAATTAGAATTAATTTGACTGTAA
ACACAAAGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGG
TAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTA
ACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAAC
ACCGNNNNNNNNNNNNNNNNNNNGTTTTAGAGCTAGAAATAGCAAGTTAAA
ATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTT
TTCTAGACCCAGCTTTCTTGTACAAAGTTGGCATTA 
G1: GGCTCCAAAGGACTTGTACG 
G2: GACTTGTACGTGGTGGAGTA 
G3: GTATGGCAGCAACGTCACGA 
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Neoepitope analysis 
Tumor and normal sample datasets for neoepitope analysis 
DNA variant, gene expression and clinical data from The Cancer Genome Atlas 
(TCGA) were obtained in June 2016 from the Genome Data Analysis Center Firehose 
(Spring 2016 run) following dbGAP approval. DNA variants were obtained in manually-
curated mutation annotation format (MAF). Gene expression data used were normalized 
counts from the TCGA RNASeq Version 2 pipeline and included all available ‘Level_3’ 
samples. Raw tumor and normal paired whole exome sequencing reads were obtained 
through dbGaP (accession phs000178.v9.p8 ) (Tryka et al. 2014) and the NCI Cancer 
Genomics Hub. Samples selected for analysis were those with DNA variant, gene 
expression and raw DNA exome reads that could be successfully downloaded. Disease 
types included in neoepitope analyses were those with at least 15 samples for predicted 
MHC class I or MHC class II neoepitopes. A list of samples analyzed for neoepitopes is 
available for all disease types (Table 9); samples with no missense mutations were 
excluded from predicted neoepitope analyses. Tumor cellularity, purity, and ploidy 
estimates were determined using Sequenza and ABSOLUTE (Carter et al. 2012, Favero et 
al. 2014). Variant, expression, clinical, and raw data from TCGA are now available 
through Genomic Data Commons. 
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HLA class I and II predictions 
Normal tissue whole exome sequencing was used for 4-digit HLA class I and II 
typing. In cases with multiple normal tissue samples, the sample with the greatest read 
depth was used. HLA class I typing was performed on reads re-mapped with RazerS3 
(version 3.5 [2437c13]) using OptiType (version 1.3.1)(Szolek et al. 2014). This method 
significantly improves on the accuracy of first-generation HLA typing tools and has been 
independently validated on TCGA whole exome sequencing. RazerS3 was used with the 
following settings: percent-identity = 90; max-hits = 1; distance-range = 0. OptiType was 
used with default settings. HLA class II typing was performed on reads re-mapped with 
BWA (version 0.7.12) using HLAreporter (version 1.0.3)(Huang et al. 2015), which was 
updated to allow efficient parallel execution. BWA was used with default settings and the 
modified HLAreporter version used is available on Github 
(https://github.com/andrewrech/pHLAreporterII). HLA class I and II tying was validated 
to have >90% 4-digit accuracy compared to standard clinical typing using sequence-
specific oligonucleotide probe and sequence specific primer techniques. For class I and II 
typing, the highest-scoring HLA type was used for analysis; samples with inadequate 
read-depth or low-certainty typing results were excluded (< 5%). 
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Neoepitope class I and II predictions 
Variants predicted to yield missense mutations present in tumor but not normal samples 
were selected for neoepitope prediction. Human Genome Organization, RefSeq and 
Entrez identifiers were converted to Enembl transcript IDs using the R/Bioconductor 
package biomatR (version 2.30.0) (Durinck et al. 2009) and amino acid sequence 
variation nomenclature was converted to a standard input form. DNA variants were 
filtered for those in genes with RSEM normalized count expression of greater than 1. 
After filtering, a sliding window of 8-15-mer peptides centered on each variant site were 
generated. Peptides were truncated if the window length extended beyond the predicted 
translated protein sequence. Estimated binding affinity for each peptide was then 
calculated using the Python script version of the Immune Epitope Database and Analysis 
Resource (IEDB) MHC class I and II prediction tools (version 2.15) (Kim et al. 2012). The 
‘IEDB recommended’ method was chosen for predictions because it considers algorithm 
benchmarks in large scale evaluation and availability across HLA alleles 
(http://www.iedb.org/). Median values were taken when multiple prediction algorithms 
were used. For MHC class I predictions, peptides with a median half-maximum 
inhibitory concentration of less than 5000nM or less than 50nM for a sample’s 
corresponding HLA types were classified as potential MHC binders and potential 
neoepitopes, respectively. For MHC class II predictions, peptides with a percentile rank of 
less than 4 or less than 1 were classified as potential MHC binders and potential 
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neoepitopes, respectively. Generator mutations were defined as missense sites generating 
one or more neoepitopes. The above pipeline for generating peptides, predicting MHC 
class I/II binding affinity and interpreting predictions for normal and mutant peptides is 
freely available as an R package and can be obtained from GitHub 
(https://github.com/andrewrech/Neoepitopes). See also Chapter 7: Software. 
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Survival analysis 
Survival used in the Kaplan-Meier estimates was determined as the number of 
days from diagnosis until death or last contact. Analyses were conducted using all 
samples or by disease type; age, gender and tumor stage were assessed as potential 
confounders. Disease types with fewer than 15 total samples across subgroups analyzed 
were excluded. The R package ‘survival’ (version 2.39-5) was used to construct Kaplan-
Meier curves. 
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Random forest analysis 
Random forest analysis was conducted using the randomforestSRC R package 
(version 2.3.0) as previously described (Ishwaran et al. 2014, Twyman-Saint Victor et al. 
2015). Random forest analysis is a multivariable non-parametric ensemble partitioning 
tree method for modeling classification, regression, or survival problems (Breiman 2001, 
Chen & Ishwaran 2012). This approach can be used to model the effect of multiple input 
variables and their interactions on a response variable of interest. Two-thirds of available 
samples are randomly chosen for model building and the result is then cross-validated 
using the remaining (out-of-bag, OOB) samples. Missing values were imputed and 
classification models were built using the following parameters: ntree = 500; nodesize = 2; 
nsplit = 10; mtry = (number of model variables)3/4. A Gini index splitting rule was used 
for classification and downsampling was used when the number of samples in each class 
differed by > 5-fold.  
Variables were then ranked by minimal depth (MD), a dimensionless statistic that 
measures variable predictiveness in tree-based models. MD is defined as the shortest 
distance between the root node of a tree and the parent node of a maximal subtree, which 
is the largest subtree whose root node splits on the variable. Smaller MD values indicate 
greater predictiveness and a tree-averaged threshold MD was used to classify variables as 
predictive using the model-building two-thirds of samples. Once predictive variables 
were identified, the model was then re-fit using these variables and tested against the 
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remaining out-of-bag samples. If the number of input variables exceeded the number of 
samples by a factor of > 10, variable hunting was employed to calculate minimal depth 
prior to variable selection and forest re-fitting. Variable hunting is a regularized 
algorithm that exploits maximal subtrees for more effective variable selection under 
conditions where many noisy variables exist (Ishwaran et al. 2010). With variable 
hunting, the high dimensional feature space is divided into multiple smaller subspaces to 
better estimate minimal depth, which is returned as the average for each variable across 
subspaces. 
Idetermined model performance using geometric mean accuracy (1-mean OOB 
error rate across replications) and F-score because Iam primarily interested in the 
predictiveness of models for all response variable classes. Relative stability was 
determined using the normalized Brier score for each model, a proper score function that 
measures the mean squared difference between the predicted outcome probabilities from 
a random forest model and the actual outcome tested using OOB samples. A normalized 
Brier score of 100 indicates random guessing; a value of 0 indicates perfect prediction. 
Each analysis was bootstrapped over n > 10 iterations with replacement and model 
performance was determined by averaging OOB error rate/F-score, normalized Brier 
score and minimal depth across bootstrap iterations. A randomly selected set of 30 non-
predictive genes were used as to generate negative control models. Models were 
considered significant if they met the following criteria: normalized Brier score < 90, 
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geometric mean accuracy > 0.6, normalized Brier score relative to negative control < 0.8, 
and geometric mean accuracy relative to control > 1.2. Negative control models were 
non-predictive. 
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Other computational analyses 
Gene expression analysis tumor types and datasets 
Data for tumor types available from TCGA were accessed in December 2015 
following dbGAP approval and represent only untreated primary tumors (defined by the 
TCGA pathologist as “pancreatic ductal adenocarcinoma” (Table 6). Each tumor sample 
is paired with a normal tissue sample providing a germline reference. The following 
tumor types (project code and n = sample size) were selected: kidney renal clear cell 
carcinoma (KIRC, n = 606), lung adenocarcinoma (LUAD, n = 116), cervical squamous 
cell carcinoma and endocervical adenocarcinoma (CESC, n = 309), lung squamous cell 
carcinoma (LUSC, n = 553), pancreatic adenocarcinoma (PAAD, n = 134), stomach 
adenocarcinoma (STAD, n = 418), head and neck squamous cell carcinoma (HNSC, n = 
566), colon adenocarcinoma (COAD, n = 328), skin cutaneous melanoma (SKCM, n = 
105 primary tumors), bladder urothelial carcinoma (BLCA, n = 427), esophageal 
carcinoma (ESCA, n = 196), liver hepatocellular carcinoma (LIHC, n = 371), thyroid 
carcinoma (THCA, n = 572), ovarian serous cystadenocarcinoma (OV, n = 309), 
glioblastoma multiforme (GBM, n = 169), and prostate adenocarcinoma (PRAD, n = 
555). Manually curated DNA variant mutational annotation format and tumor mRNA 
expression were obtained for each disease type from Broad Firehose 
(http://gdac.broadinstitute.org). Raw DNA reads (.bam format) used for BMR calculation 
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coverage estimates and HLA typing were accessed via the NCI Cancer Genomics Hub 
(https://cghub.ucsc.edu/). GISTIC2.0 (Mermel et al. 2011) individual copy number data 
for the PDA dataset was obtained from the TCGA Data Portal (https://tcga-
data.nci.nih.gov). 
RNA sequencing-based gene expression data and analysis  
Data were normalized following the method of (Rooney et al. 2015). Briefly, total 
raw read counts per gene were divided by the gene’s maximum transcript length to 
represent a coverage depth estimate. Coverage estimates were then scaled to sum to a 
total depth of 1e6 per sample and can be interpreted as Transcripts Per Million (TPM) 
(Rooney et al. 2015). Gene set variation analysis (GSVA) was performed using the 
R/Bioconductor package “GSVA” because it implements a non-parametric unsupervised 
method to measure gene set enrichment across a dataset. The sample-wise enrichment 
score for a given gene set is calculated using a Kolmogorov-Smirnov (KS)-like random 
walk statistic. Statistical ranking for GSVA scores for the cytolytic index by the top decile 
and bottom quartile were defined as cytolytic-high and cytolytic-low, respectively. 
Unsupervised hierarchical clustering, using complete linkage with the distance metric 
equal to 1 minus the Pearson correlation coefficient, was also performed using the GSVA 
scores for each dataset. Principal components analysis between cytolytic-high and low 
PDA tumors was calculated using the 5,000 most variable genes. Differential gene 
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expression analysis between cytolytic-high (top 10th decile cytolytic index) and cytolytic-
low (bottom 25th quartile cytolytic index) across TCGA datasets was calculated using 
gene-level raw counts in the R/Bioconductor package “limma” with voom transformation 
with quantile normalization (Law et al. 2014). Lowly expressed genes with less than 1 
count per million in fewer than half of the samples in a dataset were excluded for 
differential gene expression analysis. Genes with BH-adjusted p values ≤ 0.1 were 
considered differentially expressed. All plots and graphs were generated using the R 
package “ggplot2” (Wilkinson 2011).  
Mutation and copy number analysis 
Significantly mutated genes (SMGs) in cytolytic subtypes of PDA were calculated 
using the Mutational Significance in Cancer (MuSiC Genome Suite) (Dees et al. 2012). 
MuSiC identifies SMGs with a significantly higher mutation rate than the background 
mutation frequency (BMR) for a given gene calculated across the entire sample 
population. The threshold for significance was a false discovery rate of 0.1. Mutational 
spectra across cytolytic subtypes of PDA were determined as previously described 
(Rooney et al. 2015, Witkiewicz et al. 2015). Somatic copy number alterations in each 
TCGA PDA sample were counted by taking the sum of segment mean changes ≥ 0.6 and 
≤ -0.4 between somatic and normal samples. Tumor cellularity and purity estimates were 
determined using Sequenza and ABSOLUTE (Carter et al. 2012, Favero et al. 2014).  
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Other computational and statistical software 
The following R (https://www.r-project.org/, version 3.3.1) packages were used: 
data.table (http://r-datatable.com, version 1.9.6) (general data analysis), stats (version 
3.3.2, analysis of variance, spearman’s rank correlation coefficients, and Student’s T test, 
Benjamini & Hochberg false discovery rate adjustment), pheatmap (https://CRAN.R-
project.org/package=pheatmap, version 1.0.8) (heatmap generation), ggRandomForests 
(version 2.0.1)(Ehrlinger 2015) (random forest graphics), HiveR (https://CRAN.R-
project.org/package=HiveR, version 0.2.55) (hive plots), ggplot2 (version 2.1.0) (other 
graphics), cowplot (https://CRAN.R-project.org/package=cowplot, version 0.6.3) (figure 
layouts). Data ranked for classification into high vs. low groups was scaled from 0 to 100 
using an empirical cumulative distribution function and conducted within each disease 
type to avoid confounding analyses by comparing highly imbalanced sample subsets. 
Hierarchal clustering with complete linkage was used to order heatmap axes. 
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Table 1: List of flow cytometry antibodies 
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CHAPTER 3 – Radiation and Dual 
Checkpoint Blockade Activates Non-
Redundant Immune Mechanisms in 
Cancer 
 Much of Chapter 3 has been published, see Manuscripts (page xi). 
Introduction and results 
Anecdotal clinical reports suggest that RT may cooperate with anti-CTLA4 to 
systemically enhance melanoma response; (Postow et al. 2012) however, this combination 
has not been reported in a clinical trial. To examine the feasibility and efficacy of RT 
combined with immune checkpoint blockade, a phase I clinical trial of 22 patients with 
multiple melanoma metastases was initiated (Table 2). A single index lesion was 
irradiated with hypofractionated RT, delivered over two or three fractions, followed by 
four cycles of the anti-CTLA4 antibody ipilimumab (Figure 6a). Accrual was completed 
in three out of four RT dose levels, and treatment was well tolerated (Table 3). Evaluation 
of the unirradiated lesions by CT imaging using Response Evaluation Criteria in Solid 
Tumors (RECIST) demonstrated that 18% of patients had a partial response (PR) as best 
response, 18% had stable disease (SD), and 64% had progressive disease (PD) (Figure 2a). 
For example, patient PT-402 showed a large reduction in sizes of unirradiated tumors and 
64 
 
a partial metabolic response by positron emission tomography (PET) (Figure 2b). None 
of the 12 patients evaluated by PET had progressive metabolic disease in the irradiated 
lesion (Figure 6b, Table 4). The median progression-free survival (PFS) and overall 
survival (OS) was 3.8 and 10.7 months with median follow-up of 18.4 and 21.3 months 
(18.0 and 21.3 for patients without event), respectively (Figure 2c). 
Although responses were observed, the majority of patients in this trial did not 
respond. To understand the contribution of RT to immune checkpoint blockade and to 
discover mechanisms of resistance, I utilized the B16-F10 melanoma mouse model in 
collaboration with Dr. Twyman Saint Victor and others. Mice with bilateral flank tumors 
received anti-CTLA4, irradiation of one tumor (index) using a micro-irradiator, or both 
treatments delivered concurrently (Figure 2d). The best responses in both tumors 
occurred with RT + anti-CTLA4. RT given before or concurrently with CTLA4 blockade 
yielded similar results (Figure 6c). Complete responses (CRs) were CD8 T cell-dependent, 
and mice with CRs also exhibited CD8 T cell-dependent immunity to tumor re-challenge 
(Figure 6d-e). However, similar to the clinical trial, only approximately 17% of mice 
responded. To better understand determinants of response, cell lines were derived from 
unirradiated tumors that relapsed after RT + anti-CTLA4 (Res 499 and Res 177). 
Resistance was confirmed in vivo and was not due to intrinsic RT resistance (Figure 7a-c). 
Random forest (RF) machine learning analysis (Ishwaran et al. 2010, 2011) of tumor 
infiltrating lymphocytes (TILs) demonstrated that the top predictor of resistance, as 
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measured by variable importance scores and selection, was the CD8+CD44+ to Treg 
(CD8/Treg) ratio (Figure 2e, Figure 7d). In resistant tumors, the CD8/Treg ratio failed to 
increase after RT + anti-CTLA4 as it did in sensitive tumors because CD8+CD44+ T cells 
did not significantly expand despite reduction in regulatory T cells (Figure 2f). Other 
immune variables associated with resistance were also related to the failure to accumulate 
CD8 effector T cells. 
The prevalence of CD8 effector T cells can be blunted by mechanisms that 
interfere with T cell function. Transcriptomic profiling of Res 499/177 tumors revealed 
that PD-L1 was among the top 0.2% of upregulated genes that make up a RT + anti-
CTLA4 “resistance gene signature” (Figure 7e). Other genes include interferon stimulated 
genes, which may promote immune suppression through PD-L1 (Teijaro et al. 2013, 
Wilson et al. 2013). Similarly, PD-L1 was co-expressed with the resistance signature in 
tumors from a previously reported (Jonsson et al. 2010) cohort of metastatic melanoma 
patients (Figure 2g). This increase in PD-L1 was observed on melanoma cells devoid of 
contaminating stromal cells, and a comparable increase was similarly seen in the Res 237 
murine breast cancer cells (Figure 2h), which was selected from the TSA line for 
resistance to RT + anti-CTLA4 (Figure 7f-g). In contrast, expression of other inhibitory 
receptors and their ligands nominated by gene profiling did not suggest an obvious role 
in resistance (Figure 7h-i). Indeed, genetic elimination of PD-L1 on Res 499 cells by 
CRISPR (Figure 7j) restored response to RT + anti-CTLA4 by increasing survival from 
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0% to 60% (Figure 2i). Thus, an increase in PD-L1 on tumor cells observed in multiple 
cancer types can be a dominant resistance mechanism to RT + anti-CTLA4. 
Elevated levels of PD-L1 can promote T cell exhaustion, a state characterized by 
dysfunction in T cell proliferation and effector function (Wherry 2011). Exhausted T cells 
co-express the PD-L1 receptor PD1 and the transcription factor Eomes(Paley et al. 2012) . 
Reversal of exhaustion, known as reinvigoration, is marked by an increase in the 
proliferation marker Ki67 and the cytotoxic protein GzmB within the exhausted T cell 
pool. In both untreated parental and resistant tumors, approximately 20% of CD8 effector 
T cells co-expressed PD1 and Eomes, and only a minority of these cells were 
Ki67+GzmB+, indicating that a significant fraction was exhausted (Figure 3a-b). In B16-
F10 tumors, RT + anti-CTLA4 markedly increased both the proportion of PD1+Eomes+ 
CD8 T cells and the proportion that were Ki67+GzmB+ within this subset. In contrast, in 
resistant tumors the average proportion of PD1+Eomes+ T cells that were Ki67+GzmB+ 
only marginally increased after RT + anti-CTLA4; however, addition of anti-PD-L1 
increased this to levels observed in parental tumors treated with only RT + anti-CTLA4. 
The frequency of CD8+CD44+ TILs and the CD8/Treg ratio also increased (Figure 3c), 
and these were strongly correlated with the proportion of PD1+Eomes+ CD8 effector T 
cells that were Ki67+GzmB+ (Figure 8a). Importantly, addition of anti-PD-L1 improved 
responses of resistant Res 499 tumors after RT + anti-CTLA4 (Figure 8b-c). For treatment 
naïve tumors, responses were even more dramatic as the addition of either anti-PD-L1 or 
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anti-PD1 to RT + anti-CTLA4 markedly improved survival and increased CRs to 80% 
(Figure 3d, Figure 8d-f). On average, 58% of mice with CRs after adding anti-PD-L1 or 
anti-PD1 were alive 90+ days after tumor rechallenge, and similar improvements were 
observed with Res 237 breast cancer tumors after addition of PD-L1 blockade (Figure 8g-
i). Thus, elevated PD-L1 on tumor cells results in persistent T cell exhaustion that impairs 
the CD8/Treg ratio. Addition of PD-L1 blockade inhibits resistance and results in long-
term immunity. 
Notably, RT is needed to achieve high CR rates as dual checkpoint blockade 
proved inferior to dual checkpoint blockade plus RT (Figure 3d), a requirement 
additionally seen in a pancreatic cancer model (Figure 8j). The superiority of triple 
therapy in multiple cancer types suggests non-redundant mechanisms for each treatment. 
To examine this notion, I assessed treatment-related changes in TILs from unirradiated 
tumors. RF modeling of immune cell profiles confirmed that anti-CTLA4 predominantly 
caused a decrease in regulatory T cells, anti-PD-L1 strongly increased CD8 TIL 
frequency, and the blockade of both increased the CD8/Treg ratio (Figure 4a-b, Figure 
12a). In contrast, RT caused only a modest increase in CD8 effector T cells; however, TCR 
sequencing revealed that this was accompanied by increased diversity of TCR clonotypes, 
which could be observed even in the presence of CTLA4 blockade (Figure 4c-d). Thus, 
within the tumor microenvironment, CTLA4 blockade primarily decreases regulatory T 
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cells, PD-L1 blockade predominantly reinvigorates exhausted CD8 effector T cells, and 
RT diversifies the TCR repertoire of TILs from unirradiated tumors. 
When I extended these initial findings in the pancreatic cancer model to include 
both an index and unirradiated tumor, I found that unirradiated pancreatic tumors were 
resistant to RT + dual checkpoint blockade (Figure 9a-b). I hypothesized that this failure 
may be explained by a relative lack of antitumor immunity and corresponding immune 
suppressive microenvironment at baseline in the KrasLSL-G12D/+,LSL-p53LSL-R172H/+,Pdx1-Cre 
(KPC) pancreatic model, (Bayne et al. 2012, Beatty et al. 2011, Clark et al. 2009, 
Hingorani et al. 2005) mirroring human disease (Clark et al. 2009). Indeed, despite high 
intratumoral expression of the PD1–PD-L1 axis, PDA tumors are resistant to dual 
checkpoint blockade alone (Winograd et al. 2015). To evaluate this hypothesis, I induced 
T cell immunity with anti-CD40, which facilitates vaccination against tumor cells and can 
potentially synergize with agents that induce immunogenic cell death such as RT 
(Winograd et al. 2015). Addition of anti-CD40 to RT + dual checkpoint blockade resulted 
in sustained complete responses in 50% of mice (Figure 9c), restoring the two tumor KPC 
pancreatic model response rate to that observed in B16-F10 without anti-CD40. However, 
addition of anti-CD40 did not further improve responses in B16-F10 when mice were 
challenged with ten times the standard number of tumor cells (Figure 9d), suggesting that 
the KPC immune microenvironment creates a distinct additional requirement for 
immune activation.  
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Further investigation revealed that the early antitumor immune response to RT + 
dual checkpoint blockade + anti-CD40, but not overall survival, was independent of CD4 
and CD8 T cells (Figure 10), consistent with the hypothesis that CD40 exerts an 
antitumor effect through the activation of innate lymphocytes (Beatty et al. 2011). I found 
that changes in both adaptive and innate immune populations during the peak immune 
response scored as top variables in a highly accurate random forest model predicting 
treatment group, for both RT and RT + dual checkpoint blockade + CD40 (Figure 11). 
To investigate if treatment effects on TILs were propagated to the peripheral T cell 
pool, I examined spleen and blood in the B16-F10 model. As observed in TILs, RT + anti-
CTLA4 reinvigorated exhausted PD1+Eomes+ splenic CD8 T cells, and this reinvigoration 
was further enhanced by addition of anti-PD-L1 (Figure 4e-f). Reinvigoration after 
addition of anti-PD-L1 was also accompanied by a large expansion of a small subset of 
the top 100 most frequent TCR clonotypes found in TILs (Figure 4g). Remarkably, some 
clones reached a frequency in the post-treatment blood of over 20% after RT and dual 
checkpoint blockade (Figure 4h). With anti-CTLA4 +/- RT, peripheral T cell clonal 
expansion was modest, which parallels the low CR rates following this treatment. RT 
alone was insufficient to drive peripheral T cell expansion, despite increasing TCR 
repertoire diversity of TILs, but did promote qualitative alterations in the TCR repertoire 
of the most expanded clonotypes. Unsupervised analysis using the average CDR3 amino 
acid features (Atchley et al. 2005, Thomas et al. 2014) demonstrated that the TCRs of the 
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most frequent clonotypes in the post-treatment blood formed two readily apparent 
clusters based on RT treatment (Figure 4i). In contrast, the most frequent clonotypes 
from pre-treatment blood and randomly sampled clonotypes from post-treatment blood 
did not separate into clusters, consistent with differences in CDR3 amino acid properties 
being an effect of RT only observed in the most expanded clones (Figure 12b-c). The 
separation into two clusters was driven by differences in the CDR3 occupancy profile of 
short amino acid sequences belonging to distinct subsets differing in size, polarity, and 
electrostatic charge (Figure 12d-e). 
To determine if treatment and resistance-related changes in peripheral T cells can 
constitute a biomarker for tumor response, I modeled the effects of reinvigoration, 
exhaustion, and the CD8/Treg ratio. Specifically, I used 1) the percent PD1+ splenic CD8 
T cells that are Eomes+ to integrate the burden that exhausted T cells might exert, 2) the 
percent PD1+ CD8 T cells that are Ki67+GzmB+ as a measure of potential reinvigoration, 
and 3) the CD8/Treg ratio as a barometer for the suppressive potential of regulatory T 
cells. The overall prediction accuracy of the model was 84%, and variables for T cell 
reinvigoration and exhaustion were the most predictive, followed by the CD8/Treg ratio 
(Figure 13a-b). Moreover, the percentage of PD1+ CD8 T cells that were Eomes+ was a 
striking modifier of the likelihood of CR as nearly all observed CRs occurred when the 
percent Ki67+GzmB+ in PD1+ CD8 T cells was high but the relative size of the 
PD1+Eomes+ exhausted population was not (Figure 5a). Similar relationships existed with 
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the CD8/Treg ratio, and prediction using T cells from peripheral blood yielded highly 
similar results (Figure 13c-e). 
In order to assess whether immune predictors discovered in mice could be shared 
with patients, I examined peripheral T cells and tumor biopsies from patients on the 
clinical trial of RT + anti-CTLA4. For all 10 patients with available pre- and post-
treatment blood, two had PRs in unirradiated tumors and PFS significantly longer than 
the median. For both of these patients, the percentages of Ki67+GzmB+ increased in 
PD1+Eomes+ CD8 T cells after treatment while the proportion of PD1+Eomes+ T cells 
remained at or below the mean (Figure 5b). In contrast, patients with a high percentage of 
PD1+Eomes+ T cells post-treatment did not have PRs and had a short PFS, regardless of 
reinvigoration. Comparison of patient PT-402, who had extended PFS/PR (Figure 2a-b), 
with patient PT-102, who had short PFS/PD, demonstrates how reinvigoration is 
associated with response to RT + anti-CTLA4 as it is in mice (Figure 5c vs. Figure 13f-g 
and Figure 4e-f). Examination of pre-treatment tumor biopsies from patients PT-402 and 
PT-102 (Figure 5d), and from all patients with available biopsy (Table 5), revealed that 
PD-L1lo intensity on melanoma cells (Figure 14a) was associated with reinvigoration of 
PD1+Eomes+ and of PD1+ CD8 T cells after RT + anti-CTLA4, while PD-L1hi status was 
associated with persistent exhaustion (Figure 5e, Figure 14b). None of the patients with 
PD-L1hi on melanoma cells had a CR/PR, and all rapidly progressed and died (Figure 5f-
g). PD-L1 status on macrophages was neither associated with reinvigoration nor 
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independently predictive of PFS (Figure 14c-d). Thus, collective results from patients and 
mice suggest that elevated PD-L1 on melanoma cells inhibits T cell function and tumor 
response to RT + anti-CTLA4. 
Discussion 
In collaboration with Dr. Twyman Saint Victor and others, I investigated RT + 
anti-CTLA4 in mice and patients to understand mechanisms of both response and 
resistance (Figure 14e). Anti-CTLA4 predominantly inhibits regulatory T cells, increasing 
the CD8/Treg ratio as previously described, (Curran et al. 2010) and results in modest 
peripheral expansion of TCR clonotypes in the tumor, also consistent with other reports 
(Cha et al. 2014, Robert et al. 2014). RT diversifies the TCR repertoire of TILs and shapes 
the repertoire of expanded clones. My observations suggest that the favorable immune 
changes in TILs after immune checkpoint blockade promote their peripheral clonal 
expansion. When combined with increased TCR repertoire diversity afforded by RT, 
selection and oligo-clonal peripheral expansion of clones with distinct TCR traits are 
favored. Although the cause and consequence of these repertoire changes remain to be 
defined, RT can alter peptide presentation (Reits et al. 2006), and CDR3 changes after M. 
tuberculosis infection have been hypothesized to be antigen-driven (Thomas et al. 2014). 
Resistance to RT + anti-CTLA4 can ensue due to elevated PD-L1 on cancer cells driving 
T cell exhaustion, a process that can be antagonized by PD-L1 blockade. I additionally 
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demonstrated that immune parameters from peripheral T cells that relate the size of the 
exhausted T cell population, reinvigoration, and the CD8/Treg ratio can predict response 
to RT combined with immune checkpoint blockade. However, severely exhausted T cells 
may regain only limited function after reinvigoration (Paley et al. 2012, Wherry 2011), 
explaining why the correlation between reinvigoration and response declines when the 
exhausted T cell pool is large. Although tumors with genetic elimination of PD-L1 in 
melanoma cells can still relapse, suggesting resistance through other pathways and/or 
PD-L1 on non-tumor cells, the upregulation of PD-L1 by cancer cells is a dominant 
resistance mechanism. Furthermore, data from the murine KPC model suggest that 
combinatorial therapy with anti-CD40 sensitizes PDA tumors to RT + dual checkpoint 
blockade. Thus, RT + dual checkpoint blockade, in combination with additional immune 
priming, can elicit curative, systemic antitumor T cell responses even in refractory tumor 
types. Lastly, the shared findings between mice and patients predict that addition of PD-
L1/PD1 blockade to RT + anti-CTLA4 may show significant efficacy in clinical trials. 
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Tables 
Table 2. Demographics and baseline characteristics for patients on phase I clinical trial of 
radiation 1 anti-CTLA4 for metastatic melanoma. 
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Table 3. Grade 3 and 4 toxicities from phase I clinical trial of radiation 1 anti-CTLA4 for 
metastatic melanoma. 
 
Two dose levels in two strata were tested. Stratum 1 (lung/bone) used 8 Gy 3 2 or 
8 Gy 3 3. Stratum 2 (liver/subcutaneous) used 6 Gy 3 2 or 6 Gy 3 3. Six patients for each 
dose level were planned. All dose levels met accrual except 8 Gy 3 3 before trial closure. 
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Table 4. Stratum, irradiated sites, and response for patients on clinical trial. 
 
Response of the local irradiated site (Local) and distant unirradiated sites (Dist) 
were determined by CT and PET/CT. Percent change from baseline for distant lesions 
measured by CT are indicated using RECIST and change measured by PET/CT are 
indicated by PERCIST. The irradiated Tumor was not included in RECIST measurements 
per RECIST guidelines due to radiation-related effects precluding accurate CT 
measurements (for example, patient ID 1 and 9). NA indicates the value was not 
measurable based on criteria. Progression of disease due to new lesion(s) before re-
imaging (POD New) or due to clinical progression (POD Clin) is also indicated. PD, 
progression of disease; PR, partial response; SD, stable disease; CMR, complete metabolic 
77 
 
response; PMR, partial metabolic response; PMD, progressive metabolic disease. Patient 
ID 3 is patient PT-102, and patient ID 4 is patient PT-402. 
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Table 5. Melanoma biopsy sites and PD-L1(hi) status of melanoma cells from patients on 
clinical trial. 
 
Recent biopsy was optional for enrolment on the clinical trial. Tumor tissue from 
all patients with recent biopsy was used. PD-L1 status was determined by examination of 
membrane staining on melanoma cells. PD-L1(hi) was classified as 21 on at least 1% of 
cells. Patient ID 3 is patient PT-102, and patient ID 4 is patient PT-402. 
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Figure 2. RT + anti-CTLA4 promotes regression of irradiated and unirradiated tumors and is inhibited by PD-L1 on tumor cells
80 
 a) Waterfall plot of unirradiated tumors after RT to a single index lesion with 
anti-CTLA4. Dashed lines are thresholds for PD (red) and PR (blue). * Patients with new 
lesions. ** Clinical progression without imaging. b) PET/CT images of irradiated (white 
arrows) and unirradiated (yellow arrows) tumors from patient PT-402. c) PFS and OS for 
all patients (dashed lines: 95% CI). d) B16-F10 tumor growth after RT to the index tumor 
(n=8), anti-CTLA4 (C4) (n=9), anti-CTLA4 and RT to the index tumor (n=18), or no 
(control) treatment (n=9). The p-values are comparisons with control. Pie chart shows 
%CRs (yellow). See Figure 3d for survival. e) Heat map showing relative abundance of 
immune cells or their ratios from tumors that are resistant (black hatch) or sensitive to 
RT + anti-CTLA4. Boxplot shows bootstrap importance scores for each variable. Higher 
values (red) are more predictive. f) Change in T cell subsets or their ratio after RT + anti-
CTLA4 for sensitive parental (Sen) or resistant (Res) tumors. Values are subtracted from 
average of untreated controls. Red line is mean. g) Heat map of resistance gene signature 
and PD-L1 across human melanoma. p < 0.001 by gene set enrichment analysis. h) 
Expression of PD-L1 on Res 499 compared to B16-F10 melanoma cells and of Res 237 
compared to TSA breast cancer cells. Isotype control (IgG). i) Total tumor volume from 
PD-L1 knockout (KO) or control (WT) Res 499 and corresponding survival.  
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Figure 3. Addition of PD-L1 blockade reinvigorates exhausted T cells and improves 
response to RT + anti-CTLA4.  
 a) Representative contour plot of CD8 effector T cells from B16-F10 or Res 499 
tumors after RT and anti-CTLA4 (C4) +/- anti-PD-L1 (P1) examined for PD1 and Eomes 
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(top row), followed by examination of the PD1+Eomes+ subset for Ki67 and GzmB 
(bottom row). Schema shows exhaustion and reinvigoration markers. b) Proportion of 
PD1+Eomes+ CD8 T cells that are either Ki67-GzmB- or Ki67+GzmB+. c) Changes in T cell 
subsets and their ratio from Res 499 tumors. d) Survival of mice with B16-F10 tumors 
(n=18 for RT+C4, n=5 for others). Shown are overall p-values.  
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Figure 4. RT, anti-CTLA4, and anti-PD-L1 have distinct effects on the TCR repertoire, 
regulatory T cells, and T cell exhaustion. 
a) Heat map of changes in the frequency of immune cells or their ratios from B16-
F10 tumors. Black hatches indicate treatment. Bar plots show bootstrap importance 
scores (mean +/- SE) that assess changes in immune parameters predicted by treatment 
type (read row-wise). Higher values (yellow) represent stronger association. b) T cell 
subsets and their ratios. c) Frequency distribution (dashed line is 0.5%) and d) boxplot of 
diversity index (0: clonal, 1: fully diverse) for most frequent TCR clonotypes found in 
TILs of unirradiated B16-F10 tumors after RT and/or anti-CTLA4. Boxplot summarizes 
data for mice treated with anti-CTLA4 (NoRT) or RT +/- anti-CTLA4 (+RT). e) 
Representative contour plots and f) ratios examining PD1+Eomes+ splenic CD8 T cells 
from mice with B16-F10 tumors for Ki67+GzmB+ (reinvigorated) or Ki67-GzmB- 
(exhausted) subsets. g) TCR clonal frequency in post-treatment blood vs. TILs (top row) 
or vs. pre-treatment blood (bottom row). Quadrant boundaries are top 5% quantiles from 
the control. Clones below detection in pre-treatment blood are assigned upper bounds 
(blue). h) Maximum clonal frequency in post-treatment blood (dot) of the most frequent 
TCR clonotypes found in TILs. i) Distances to cluster centroids for the average CDR3 
amino acid features of the five most frequent clones in pre- or post-treatment blood from 
mice treated with (red) or without (orange) RT. Membership into two clusters (circles 
and squares) determined by k-means.  
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Figure 5. Tumor PD-L1 and T cell exhaustion and reinvigoration can predict response in 
mice and patients. 
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a) Percent PD1+ CD8 T cells that are Eomes+ vs. Ki67+GzmB+ after RT combined 
with checkpoint blockade. Values are subtracted from average of untreated controls. Each 
circle represents a mouse. Probability of CR (proportional to circle size), prediction error 
rate, and quadrant boundaries are estimated from an RF model. b) Percent Eomes+PD1+ 
CD8 T cells in post-treatment blood vs. change in % PD1+Eomes+ CD8 T cells that are 
Ki67+GzmB+ after treatment. Each circle represents a patient. PFS is proportional to circle 
size and quadrant boundaries are average values for patients under the mean PFS. 
Concordance index of the RF model is 0.59. c) Contour plot of peripheral blood CD8 T 
cells from patients PT-102 and PT-402 examined for PD1 and Eomes (top row), followed 
by examination of the PD1+Eomes+ subset for Ki67 and GzmB (bottom row). d) PD-L1 
staining from corresponding tumor biopsies. e) Change in % Ki67+GzmB+ in 
PD1+Eomes+ CD8 T cells vs. PD-L1 status of melanoma cells from all patients with 
available pre- and post-treatment blood. f) RECIST response, g) PFS, and OS stratified by 
PD-L1 status of melanoma cells.  
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Figure 6. Patients and mice treated with RT + anti-CTLA4 for melanoma. 
a) Twenty-two stage IV melanoma patients (M stage indicated) were stratified by 
treatment site of a single index metastasis, which was the irradiated tumor. Two dosing 
levels (DL) for stereotactic body radiation (SBRT) were in each stratum. b) Waterfall plot 
of the RECIST % change from baseline of unirradiated tumors annotated to indicate 
metabolic responses by PET/CT (hatches above plot) and response of the irradiated index 
tumor as measured by CT and PET/CT (hatches below plot). RECIST criteria do not 
include irradiated tumors. Legend shows color-codes for response after CT or PET/CT 
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(parenthesis). PMD: progressive metabolic disease; SMD: stable metabolic disease; PMR: 
partial metabolic response; CMR: complete metabolic response. White hatches indicate 
no imaging obtained. See Table 3. Grade 3 and 4 toxicities from phase I clinical trial of 
radiation 1 anti-CTLA4 for metastatic melanoma. c) Survival (right) and total tumor 
growth (bottom) after RT with either concurrent or sequential anti-CTLA4 compared to 
anti-CTLA4 (C4) or RT alone. The regimens and the standard regimen used for all other 
melanoma experiments are illustrated (left). The p-values for tumor growth are compared 
to anti-CTLA4. d) Survival after RT and/or anti-CTLA4 with or without T cell depletion 
(n=5-10) using anti-CD8 (CD8). Shown are overall p-values. The p-value for RT + anti-
CTLA4 with and without anti-CD8 is p=0.005. Control is an isotype-matched antibody. 
e) Three mice with CRs were rechallenged with B16-F10 tumors. Shown is a 
representative mouse. Arrow indicates location of regressed tumor and vitiligo-like 
condition represented by non-pigmented fur (observed in approximately 50% of mice 
with CRs). Time line starts from original tumor implantation (day 0) and values above 
marks are days after first rechallenge. Recurrence occurred only after anti-CD8 treatment 
and second rechallenge.  
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Figure 7. Tumor cells resistant to RT + anti-CTLA4 upregulate PD-L1 but not other 
candidate inhibitory receptor pathways. 
a) Unirradiated tumor growth (left: normalized, right: raw values) for mice 
implanted with Res 177 (n=21), Res 499 (n=25), and B16-F10 (n=18) melanoma cells and 
treated with RT + anti-CTLA4. For normalization, volumes were divided by average of 
untreated controls (V/Vcont) to account for differences in growth between untreated 
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tumor types. The p-values are for comparisons with B16-F10 tumors. b) Corresponding 
tumor volumes of unirradiated or irradiated index tumors at day 21 (blue line is mean). c) 
Clonogenic survival for Res 499 and B16-F10 cells (n=2). d) Selection of immune 
variables that robustly predict resistance to RT + anti-CTLA4 using minimal depth (MD). 
A variable was selected if its MD was less than a threshold value for significance. Shown 
are bootstrap distributions of MD values (left) and % bootstrap models for which the MD 
for the indicated variable was significant (right). Bootstrap mean +/- SD for the out-of-
bag prediction error rate is listed on top. e) Volcano plot of differentially expressed genes 
from resistant tumors. Horizontal black line is 5% false-discovery rate and dotted green 
line is fold-change cut-off. Ligands for select inhibitory receptors are indicated. See SI 
Table 1. f) Unirradiated tumor volumes (day 26-29) and g) survival after RT + anti-
CTLA4 for mice with bilateral tumors from TSA breast cancer cells (n=25) or from the 
Res 237 subline selected to be resistant (n=21). h) Expression of candidate T cell 
inhibitory receptor ligands on B16-F10 and Res 499. Interferon-gamma (Interferon-γ) 
responsiveness was tested. i) Boxplots show distribution of % positive CD8+CD44+ T cells 
for the indicated inhibitory receptor compared to IgG control. j) PD-L1 surface 
expression for CRISPR PD-L1 homozygous knockout Res 499 and wild type control cells. 
interferon-γ was used to induce PD-L1 and confirm abrogated response.  
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Figure 8. Addition of PD-L1/PD1 blockade antagonizes resistance to RT + anti-CTLA4, 
and optimal response to checkpoint blockade requires RT. 
a) Change in % CD8+CD44+ T cells after RT and checkpoint blockade vs. change 
in the degree of reinvigoration of exhausted T cells measured by % PD1+Eomes+ T cells 
that are Ki67+GzmB+. Values are subtracted from average of untreated control. b) Growth 
of Res 499 tumors after RT + anti-CTLA4 (C4) with and without addition of anti-PD-L1 
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(PDL1). Shown are index and unirradiated tumors from n=25 mice in each group. The p-
value is for comparison to RT + anti-CTLA4. c) Proportion of CRs (yellow) for mice with 
Res 499 tumors. d) Total tumor growth (index + unirradiated) for B16-F10 tumors after 
the indicated treatment that includes anti-PD1 (PD1) or anti-PD-L1. The p-values are for 
comparisons to RT + anti-CTLA4 (n=18, n=5 for others). Pie charts show % CRs 
(yellow). e) Survival of mice after RT + anti-CTLA4 + anti-PD1. Shown is the overall p-
value, and f) the two-way comparisons that include those from Figure 3d. g) Proportion 
of mice with CRs (yellow) after RT + anti-PD-L1 or anti-PD1 that survived 90+ days after 
tumor rechallenge at day 60 (n=12). h) Survival of mice with bilateral Res 237 breast 
cancer tumors treated with RT + anti-CTLA4 with (n=16) or without (n=21) anti-PD-L1. 
i) Proportion of CRs (yellow) for mice with Res 237 or TSA breast cancer tumors. j) 
Survival of mice with pancreatic tumors from a cell line derived from KPC mice (KrasLSL-
G12D/+;p53LSL-R172H/+;Pdx-1-Cre) (n=5 for each group). Select treatment groups are labeled 
on the plot for clarity. Overall p-value is shown.  
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Figure 9. Unirradiated pancreatic tumor resistance to RT + anti-CTLA4 + anti-PD1 is 
overcome by the addition of anti-CD40. 
(a) Experimental schema. In contrast to Figure 8, a second, unirradiated tumor 
was implanted on the opposite flank, similar to Figure 2. b) Growth of PDA tumors from 
a cell line derived from KPC mice (KrasLSL-G12D/+;p53LSL-R172H/+;Pdx-1-Cre) after no 
treatment, RT, or RT + anti-CTLA4 + anti-PD1. Shown is unirradiated tumor growth 
from n=5 mice per group (overall p < 0.001). (c- d) Survival of mice after RT and 
combinatorial antibody therapy. P values are for RT + anti-CTLA + anti-PD1 + anti-
CD40 vs. other groups (c) or as indicated (d) (n = 5-10 mice per group).  
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Figure 10. Early response to RT + anti-CTLA4 + anti-PD1 + anti-CD40 is T cell 
independent. 
(a-b) Total tumor growth (index + unirradiated) for pancreatic tumors from a cell 
line derived from KPC mice (KrasLSL-G12D/+;p53LSL-R172H/+;Pdx-1-Cre) after the indicated 
treatment for the index (a) or unirradiated (b) tumor. P value shown in (b) is for Tx vs. 
Tx + depleting antibody groups (black arrows): no treatment; 8depl: CD8-depleting 
antibody; 4depl: CD4-depleting antibody; Tx: RT + anti-CTLA4 + anti-PD1 + anti-CD40. 
(c) Survival of mice with pancreatic tumors from the experiment shown in (a-b). As 
indicated, all p values for treatment groups separated by the blank lines were less than 
0.01.   
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Figure 11. Adaptive and innate immune composition distinguishes treated vs. untreated 
pancreatic tumors. 
(a-b) Top: parallel coordinate plot showing proportion (y-axis, standard deviation 
from mean) of the indicated immune population (x-axis) across individual mice (lines). 
Red vs. blue color indicates treatment group as indicated in the legend. Bottom: 
importance (minimal depth) of the immune population to the randomforest model 
prediction of treatment group. Minimal depth is a statistic to measure predictiveness; 
accuracy of the overall models for (a) and (b) were greater than 90%.  
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Figure 12. TCR clonotypes associated with RT are not observed in random clones from 
post-treatment blood and have distinct CDR3 features. 
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a) Boxplot of the bootstrap variance explained by multivariable RF regression 
model for effect of RT, anti-CTLA4, and/or anti-PD-L1 on immune variables from TILs. 
b) K-means clustering (k=2) was used on the average CDR3 amino acid features of 
randomly sampled clones from post-treatment blood after anti-CTLA4, anti-PD-L1, 
and/or RT. Membership into each cluster was determined and the p-value for separation 
into treatment groups with and without RT was calculated. Boxplot shows log10 p-values 
from 1000 random iterations. Comparison to the p-value from the observed data (red 
dotted line) gives a simulated p < 0.001. c) Log10 p-values for separation into treatment 
groups with and without RT vs. cut-off value used to select the most frequent clones. The 
0.05 significance level is indicated (red dotted line). d) Average % occupancy in the CDR3 
of the most frequent T cell clonotypes after RT +/- checkpoint blockade (+RT, red line) or 
checkpoint blockade alone (NoRT, orange line) by contiguous short amino acid 
sequences of length three (3-tuples) belonging to e) subsets with distinct treatment-
related amino acid properties. These properties are characterized by Atchley factors, 
which measure 1) PAH: accessibility, polarity, and hydrophobicity, 2) PSS: propensity for 
secondary structure, 3) MS: molecular size, 4) CC: codon composition, and 5) EC: 
electrostatic charge. Shown (right) are the average values of each Atchley factor for amino 
acids that comprise the 3-tuples from the indicated subset (red) compared to all 
unselected 3-tuples (blue). Boxplots (left) show the proportion of 3-tuples from each of 
these subsets that are found in the CDR3s of the five most frequent clones after treatment. 
Compared to pre-treatment samples (Pre-tx), subset 6 is associated with RT +/- 
98 
 
checkpoint blockade (+RT) or checkpoint blockade alone (NoRT). Subset 1 is primarily 
associated with checkpoint blockade alone, and subset 16 is primarily associated with RT 
+/- checkpoint blockade.  
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Figure 13. Peripheral T cell exhaustion, reinvigoration, CD8/Treg ratio, and tumor PD-L1 
predict response to RT + immune checkpoint blockade. 
a) Heat map showing the relative proportions of PD1+ CD8 T cells that are 
Ki67+GzmB+ or Eomes+ and the CD8/Treg ratio for each sample (columns) subtracted 
from the average values of untreated controls. Black hatches indicated CR and treatment 
with RT + anti-CTLA4 (C4) +/- anti-PD-L1 (P1). From these data, a multivariable RF 
predictor for CR was developed. Boxplot shows bootstrap distributions of variable 
importance scores (more predictive variables have higher values), and of b) minimal 
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depth (MD), a statistic to measure predictiveness. Bar plot shows % bootstrap models for 
which the MD for the indicated variable was significant. Bootstrap mean +/- SD for the 
out-of-bag prediction error rate is listed on top. c) Probability of CR vs. change (treated 
vs. untreated control) in CD8/Treg ratio for mice with a high (blue dots) or low (red dots) 
change in % PD1+ splenic CD8 T cells that are Eomes+. d) Heat map similar to (a) except 
using T cells from peripheral blood. e) Percent peripheral blood PD1+ CD8 T cells that 
are Eomes+ vs. Ki67+GzmB+ after RT + checkpoint blockade. Values are subtracted from 
average of untreated controls. Each circle represents a mouse. Probability of CR 
(proportional to circle size), prediction error rate, and quadrant boundaries are estimated 
from the RF model. f) Representative contour plots examining splenic CD8 T cells from 
B16-F10 or Res 499 tumors for PD1 and Eomes (top), followed by examination of the 
PD1+Eomes+ subset for Ki67 and GzmB (bottom). g) Ratios of PD1+Eomes+ splenic CD8 
T cells that are Ki67+GzmB+ (reinvigorated) compared to Ki67-GzmB- (exhausted) from 
mice with Res 499 tumors.  
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Figure 14. Melanoma PD-L1 is associated with T cell exhaustion, response, and survival 
for patients treated on clinical trial of RT + anti-CTLA4. 
a) Representative images (right) for patients with biopsies showing PD-L1 
staining on tumor cells classified as PD-L1lo (top), 2+ (middle), or 3+ (bottom). Scores of 
2+ and 3+ are classified as PD-L1hi. The arrow indicates PD-L1 staining on macrophages. 
An isotype antibody negative control and positive controls are shown (left). b) Changes 
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in % Ki67+GzmB+ in PD1+ CD8 T cells after RT + anti-CTLA4 vs. PD-L1 status on 
melanoma cells from all patients with available pre- and post-treatment blood. c) 
Changes in % Ki67+GzmB+ in PD1+Eomes+ CD8 T cells (left) or in PD1+ CD8 T cells 
(right) vs. macrophage PD-L1 status. d) Hazard ratio and 95% CI for PFS from a Cox 
regression model using PD-L1 status on tumor cells and macrophages. e) Model for non-
redundant mechanisms and resistance to RT and immune checkpoint blockade.
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CHAPTER 4 – Distinct immune cytolytic 
activity and neoepitope load in human 
pancreatic cancer 
Much of Chapter 4 has been published, see Manuscripts (page xi). 
Introduction 
Pancreatic adenocarcinoma (PDA) is the third most common cause of death from 
cancer – with an overall 5-year survival rate of less than 5% – and is predicted to become 
the second leading cause of cancer mortality in the United States by 2030 (Hidalgo 2010, 
Rahib et al. 2014). The American Cancer Society predicts that for the first time, more 
patients will die annually of pancreatic cancer than breast cancer beginning in 2016 in the 
United States (Siegel et al. 2016). Recently approved combination chemotherapies for 
metastatic PDA modestly impact patient outcomes and durable remissions are rare 
(Conroy et al. 2011, Hoff et al. 2013). Several recent studies have identified distinct 
genetic and transcriptional PDA tumor and stromal subtypes, which may present 
opportunities to identify individual patients likely to respond to targeted therapies (Bailey 
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et al. 2016b, Collisson et al. 2011, Moffitt et al. 2015, Waddell et al. 2015, Witkiewicz et al. 
2015). Immune modulation is a particularly attractive approach to treatment because of 
its potential to generate durable clinical responses in the proper setting (Foley et al. 2015, 
Vonderheide & Bayne 2013). Although single-agent immunotherapies targeting the 
immune checkpoint pathways PD1/PD-L1 and CTLA4 have shown striking efficacy in 
multiple tumor types, such approaches have failed to show clinical benefit in the 
overwhelming majority of patients with PDA (Brahmer et al. 2012, Royal et al. 2010). 
Immunologically, PDA is characterized by a highly suppressive tumor microenvironment 
and a dense desmoplastic stroma, (Vonderheide & Bayne 2013, Wörmann et al. 2013) 
and for most patients there is scant intratumoral infiltration of effector T cells (Bailey et 
al. 2016b, Beatty et al. 2013). A small fraction of human PDA tumors do exhibit an 
immunogenic profile, (Bailey et al. 2016b, Fukunaga et al. 2004) and there is provocative 
evidence that survival is improved in resectable PDA patients whose tumors have higher-
than-average or unusual tumor T cell infiltration (Fukunaga et al. 2004, Hiraoka et al. 
2015, Ino et al. 2013). At present, the determinants of immune activation in PDA are 
poorly understood, providing little therapeutic guidance. 
Here, in collaboration with Drs. Balli and Stanger, I contextualize immune activity 
in PDA by expanding previous analyses to multiple MHC class I and II neoepitope types 
across 9928 human cancer samples belonging to 35 solid tumor types. Using a highly-
optimized, open source discovery pipeline, I evaluated over 400 million peptides 
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generated from over 1 million missense mutations. To characterize immune correlates, 
this analysis assessed multiple immune indices, immune- and cancer-related gene sets, 
and gene mutational status for associations with neoepitope load both in PDA and then 
across human cancer. I further assessed the overall characteristics of neoepitope load, 
type and quality in human cancer at the global level and employed random forest 
machine learning to understand complex relationships in these data and build predictive 
models at the sample and disease levels. 
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Results 
Stratification of human PDA based on cytolytic T-cell activity 
Using publicly available data from 134 primary tumor resection samples, I 
profiled the genomic and transcriptional landscape of human PDA in the context of the 
immune microenvironment. I focused on a validated gene expression signature of 
granzyme A (GZMA) and perforin-1 (PRF1) to assess intratumoral cytolytic T cell activity 
(cytolytic index; CYT) (Rooney et al. 2015). GZMA is a tryptase that induces caspase-
independent programmed cell death and PRF1 is a pore-forming enzyme that mediates 
entry of granzymes into target cells, both produced by activated cytolytic CD8 T cells and 
upregulated following response to immunotherapy (Chowdhury & Lieberman 2008, 
Herbst et al. 2014, Johnson et al. 2003, Keefe et al. 2005). Although Rooney and colleagues 
pioneered the utility of this cytolytic index broadly across many human cancers in their 
initial report, pancreatic cancer was omitted (Rooney et al. 2015). Here, to assess cytolytic 
index in PDA, I obtained RNA sequencing data from The Cancer Genome Atlas (TCGA) 
for multiple tumor types including recently released data for PDA samples (Network et al. 
2013). Consistent with previous findings, I found that cytolytic index was highest in 
kidney, lung and cervical cancers and lowest in glioblastoma, ovarian, and prostate 
adenocarcinoma (Figure 15A) (Rooney et al. 2015). The median cytolytic index of PDA 
samples was comparable to that of other cancer types, including lung squamous cell 
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carcinoma and stomach adenocarcinoma (Figure 15A) and cytolytic activity in PDA was 
significantly higher than activity in normal pancreas. (Figure 15A, inset) Interestingly, 
while PDA has a median cytolytic index similar to stomach adenocarcinoma (8.59±7.5 vs. 
8.01±11.9 CYT index), the distribution of cytolytic index is significantly narrower in PDA 
(Kolmogorov-Smirnov test, Figure 23). 
Cytolytic activity differs across established PDA subtypes 
To classify the subpopulations of PDA tumors with high versus low cytolytic 
activity, I stratified the PDA dataset by defining tumors in the top 10th percentile by 
cytolytic index as cytolytic-high (CYT High) and tumors in the bottom 25th percentile as 
cytolytic-low (CYT Low) (Figure 15B). Cytolytic-high PDA tumors were enriched for 
gene sets associated with activated CD8+, PD1high T cells, (Duraiswamy et al. 2011, Parish 
et al. 2009) confirming that expression of GZMA and PRF1 correlated with immune 
response and infiltration of CD8 cytolytic T cells (Figure 15C,  
Figure 24).  
As these data suggest that stratification based on cytolytic T cell infiltration, as 
measured by the cytolytic index, may be associated with distinct PDA subtypes, I 
determined if cytolytic activity is associated with genomic and transcriptional metrics of 
PDA tumor biology. Recent studies from multiple groups have demonstrated the 
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extensive genetic and transcriptional diversity of PDA tumors (Bailey et al. 2016b, 
Collisson et al. 2011, Moffitt et al. 2015, Waddell et al. 2015, Witkiewicz et al. 2015). PDA 
can be stratified into at least three tumor subtypes based on gene expression profiling: (1) 
Classical/Pancreatic Progenitor, (2) Squamous/Quasi-mesenchymal/Basal-like, and (3) 
ADEX (aberrantly differentiated endocrine exocrine)/Exocrine-like (Bailey et al. 2016b, 
Collisson et al. 2011, Moffitt et al. 2015). Furthermore, these PDA tumors types can 
overlap with gene programs associated with distinct stroma populations: (1) activated 
stroma, (2) normal stroma, and (3) immune gene signatures (Bailey et al. 2016b, 
Collisson et al. 2011, Moffitt et al. 2015). I assessed enrichment of gene programs defining 
PDA subtypes using the TCGA PDA dataset (Figure 16A) and their association with 
cytolytic index (Figure 16B). Cytolytic-high tumors were statistically enriched for the 
immune gene programs (GP7 and GP8) from Bailey and colleagues and the normal 
stroma gene program from Moffitt and colleagues (Figure 16B) (Bailey et al. 2016b, 
Collisson et al. 2011, Moffitt et al. 2015). Immune gene programs GP7 and GP8 contain 
markers for macrophages and T cell co-inhibition (GP7) and CD8 T cells and B cells 
(GP8) (Bailey et al. 2016b), and the normal stroma gene signature contains markers of 
pancreatic stellate cells (Moffitt et al. 2015). Pancreatic stellate cells have been linked to an 
immune suppressive tumor microenvironment through PTX3 regulation of immune 
escape by blocking antigen presentation (Baruah et al. 2006). Expression of genes defining 
the normal stroma gene program were increased in cytolytic-high tumors, suggesting a 
relationship between stromal microenvironment and T cell infiltration (Figure 16C). 
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Cytolytic-low PDA tumors had statistical enrichment of gene programs associated with 
the Classical/Pancreatic Progenitor tumor subtypes (Figure 16B). Genes involved in 
pancreatic differentiation were increased in cytolytic-low tumors suggesting an inverse 
relationship between differentiation status and immune reactivity (Figure 16D). 
Moreover, using a previously defined “immunome” gene signature of 28 distinct 
immune-cell specific markers, (Bindea et al. 2013) I found that cytolytic-high tumors 
were associated with multiple other immune cell signatures (Figure 26A). These data 
suggest that stratification of patients with PDA based on transcriptional profiling can 
differentiate between tumors with strong cytolytic T cell response and tumors for which a 
privileged immune microenvironment precludes such responses (Vonderheide & Bayne 
2013).  
Cytolytic activity correlates with distinct mutational events in PDA 
I next sought to determine if cytolytic activity correlated with distinct mutational 
profiles characterized for PDA (Alioto et al. 2015, Bindea et al. 2013, Waddell et al. 2015). 
Curated mutational data for PDA was obtained from TCGA and I identified significantly 
mutated genes occurring in cytolytic high and low PDA tumors. Cytolytic-high tumors 
had a statistically significant association with mutations in TGFbetaR1/TGFbetaR2 as well 
as HMGB3 (Figure 27A). Cytolytic-low tumors were associated with non-silent mutations 
in CDKN2A, ANKRD36, NCOA3, and HIST1H1B. Most mutations across the dataset 
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were associated with G>A and C>T transitions, and the frequency of specific 
substitutions did not differ between cytolytic high and low tumors (Figure 27B). Likewise, 
there was no association between cytolytic index and KRAS mutation type (Figure 27C).  
 PDA is characterized by increased genomic instability with extensive copy 
number alterations in both human patients and genetically engineered mouse models 
(Hingorani et al. 2005, Waddell et al. 2015, Witkiewicz et al. 2015). I next obtained the 
GISTIC2.0 analysis for PDA from TCGA and assessed copy number alterations between 
cytolytic subtypes. Cytolytic-low (but not high) tumors had recurrent copy number 
alterations at loci important in PDA, (Witkiewicz et al. 2015) including MYC, NOTCH2, 
and FGFR1 Figure 27D, right). Consistent with increased copy number alteration and 
MYC amplification, cytolytic-low tumors had increased expression of gene signatures 
associated with increased genomic instability and MYC target genes (Figure 27) (Zeller et 
al. 2003). Recurrent deletions were observed in cytolytic-low tumors at loci containing 
CDKN2A/B and SMAD4. MYC amplification has been observed in mouse models of 
hepatocellular carcinoma and human melanoma tumors and associated with reduced T 
cell infiltration and cytolytic activity, suggesting that genomic events may modulate 
inflammatory response in PDA (Linsley et al. 2014). Cytolytic-high PDA tumors did not 
have recurrent copy number losses but rather had amplifications at 4q13.1 (TECRL), 
9p13.3 (CA9, TPM2, C9orf100), and 18q11.2 (IMPACT, OSBPL1A) (Figure 27D, left). 
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Assessed globally, cytolytic-high tumors had significantly fewer somatic copy number 
alterations (SCNA events) than cytolytic-low tumors (Figure 27E-F).  
Mutational analysis of tumor samples can be hampered due to tumor cellularity 
because this reduces the ability to confidently detect somatic mutation and copy number 
alterations. To ensure that the TCGA PAAD cohort has sufficient cellularity for 
mutational analysis, cellularity estimates were calculated using ABSOLUTE (Carter et al. 
2012) and Sequenza (Favero et al. 2014). Tumor cellularity estimates did not correlate 
with either total mutation load or total copy number events in the TCGA PAAD cohort 
(Figure 30). Furthermore, TCGA PAAD cellularity estimates (59±16.9%) were 
comparable to the lung adenocarcinoma (LUAD, 52±11.8%) and stomach 
adenocarcinoma (STAD, 53±12.8%) tumor cohorts (Figure 29). Moreover, there was no 
difference in cellularity estimates between cytolytic subtypes, suggesting that observed 
differences in copy number and mutational load were not a result of variable tumor 
cellularity (Figure 30). Thus, distinct mutational and structural changes in the genome 
distinguish those PDAs with low vs. high cytolytic activity.  
High cytolytic activity in PDA does not correlate with increased neoepitope load 
To investigate the landscape of neoepitopes in human cancer, I developed a highly 
optimized pipeline for predicting neoepitopes that integrates TCGA DNA variants, gene 
112 
 
expression and raw DNA exome reads (Figure 34, see also Neoepitope analysis). Poor 
tumor sample purity can reduce the ability to confidently determine somatic variants 
from whole exome sequencing, therefore I estimated tumor DNA fraction for each 
sample analyzed using ABSOLUTE (Carter et al. 2012) and confirmed results using 
Sequenza (Waring 2006). I found wide variation across TCGA (0.79 ± 0.08) but no 
correlation between tumor DNA fraction and missense mutation burden (Figure 35). 
MHC class I and II alleles were determined using OptiType and HLAreporter, 
respectively. I validated these methods to have > 95% (MHC class I) and >90% (MHC 
class II) 4-digit accuracy compared to standard clinical typing, consistent with other 
reports, and sample HLA alleles paralleled frequencies reported for the general 
population. Using tools provided by the Immune Epitope Database and Analysis 
Resource (IEDB), I then analyzed all possible peptides generated from missense 
mutations in expressed genes for ability to bind MHC class I and II. High affinity binders 
were classified as predicted neoepitopes (median half-maximum inhibitory concentration 
of less than 50nM for MHC class I, percentile rank of less than 1 for MHC class II). 
I then determined if cytolytic activity correlated with neoepitope load in PDA, as 
has been widely suggested for cancers in general (Rooney et al. 2015). Neoepitopes, 
derived from peptides encoded by somatic tumor mutations and thus not subject to 
central tolerance in the thymus, have been demonstrated to preferentially drive T cell 
recognition of tumor cells (McGranahan et al. 2016, Schumacher & Schreiber 2015). A 
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total of 1.1 x 104 unique variants leading to 5.1 x 106 potential peptides were evaluated for 
the PDA dataset. This analysis revealed no correlation between total mutations per 
individual tumor and cytolytic index, although when viewed as a group the cytolytic-low 
tumors exhibited a slight increase in the number of mutations per tumor compared to 
cytolytic-high tumors (Figure 18A). Neoepitope load did not correlate with cytolytic 
activity in PDA, with striking examples of cytolytic-low tumors with multiple predicted 
neoepitopes and cytolytic-high tumors with few neoepitopes (Figure 18B-E). Consistent 
with the findings from the overall mutation rate, the tumor cellularity estimates did not 
correlate with the number of MHC Class I or II neoepitopes in PDA (Figure 30). In 
contrast, as expected, (Rooney et al. 2015) both lung adenocarcinoma and stomach 
adenocarcinoma showed a strong correlation between total number of mutations, 
predicted MHC class I neoepitope load, and number of mutations generating one or 
more neoepitopes in cytolytic-high tumors (top 10th percentile versus bottom 25th 
percentile ranked by cytolytic activity) (Figure 31). Stratification of patients with PDA 
based on established gene signatures (Bailey et al. 2016b, Moffitt et al. 2015) also did not 
associate with increased neoepitope load in any PDA transcriptional subtype (Figure 32). 
Taken together, these data suggest that cytolytic activity in PDA, in contrast to other 
tumor types, is not driven by increased mutation or neoepitope load. 
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Cytokine and immune checkpoint gene expression patterns differ in PDA tumors with high vs. low 
cytolytic activity 
The tumor microenvironment in PDA contains a rich cytokine milieu with both 
pro- and anti-inflammatory factors that can regulate tumorigenesis (Delitto et al. 2015). I 
therefore hypothesized that the expression of these cytokines and chemokines would be 
increased in cytolytic-high tumors across all TCGA tumor types. Consistent with this 
notion, I found that the expression of numerous pro- and anti-inflammatory cytokines 
and immune checkpoint molecules was significantly increased in cytolytic-high tumors 
across TCGA, including PDA (Figure 18F). Specifically, cytokines previously shown to 
correlate with cytolytic index – including C1QA, C1QB, C1QC, CXCL10, and CXCL9 – 
were differentially expressed in cytolytic-high TCGA tumors, including cytolytic-high 
PDA (Rooney et al. 2015). The expression of regulatory T cell markers were also 
significantly increased in cytolytic-high PDA tumors (Figure 18I).  
I next assessed whether cytolytic-high PDA tumors exhibit increased expression 
of immune checkpoint pathways. An inhibitory checkpoint index was created to assess 
the expression of key checkpoint molecules across patients with PDA (Figure 18G). The 
inhibitory checkpoint index was generated by taking the log-average expression in TPM 
of the following molecules: ADORA2A (A2AR), CD274 (PD-L1), PDCD1 (PD1), CTLA4, 
HAVCR2 (TIM3), IDO1, IDO2, PDCD1LG2 (PD-L2), TIGIT, VISTA (C10orf54), and 
VTCN1 (B7-H4). Using this index, I found a strong correlation between cytolytic activity 
115 
 
and the expression of inhibitory checkpoint genes in patients with PDA, suggesting that 
as in melanoma, (Spranger et al. 2013) immune response in cytolytic-high tumors elicits 
multiple host and tumor mechanisms of immune suppression in the tumor 
microenvironment (Figure 18H). However, CD274 (PD-L1) expression was uniformly 
low in PDA and was not differentially expressed between cytolytic subsets in PDA despite 
being increased in cytolytic-high tumors in the other TCGA datasets examined (Figure 
18F arrow). Multiple other inhibitory checkpoint molecules were expressed at markedly 
higher levels in cytolytic-high tumors (Figure 4J). While PD-L1 expression was not 
changed between cytolytic subsets in PDA, the expression of other immune checkpoint 
molecules, including IDO1, IDO2, CTLA4, and PD-L2, were differentially expressed in 
cytolytic-high PDA tumors (Figure 18J). When compared individually, the expression 
levels of PDCD1, PDCD1LG2, CTLA4, IDO2, A2AR, TIGIT, and LAG3 have the highest 
correlation with the cytolytic index and, conversely, PD-L1 and VTCN1 (B7-H4) have the 
lowest correlation (Figure 33). These data suggest that multiple immune checkpoint 
pathways, other than the PD1 axis, may mediate peripheral tolerance and immune escape 
in PDA; combinatorial targeting of these pathways may expand clinical benefit for 
patients with PDA. 
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Contextualizing PDA within the neoepitope landscape of human cancer 
To contextualize these findings in PDA with the larger landscape of neoepitopes 
across human cancer, I expanded this analytical pipeline to all available TCGA solid 
disease types. I noted significant differences in rate of neoepitope generation (percent 
predicted neoepitopes among all candidate peptides) across HLA alleles for all samples 
analyzed (Figure 36). Common class I HLA alleles A*02:01, A*11:01, B*44:02, C*05:01, 
and C*12:03 had significantly higher rates of neoepitope generation (p adj. < 0.005); 
A*01:01, A*03:01, A*24:02, B*08:01, C*04:01, and C*06:02 had significantly lower rates (p 
adj. < 0.005). For class II HLA alleles, common alleles DPA1*01/DPB1*04:01, 
DQA1*05:01/DQB1*02:01, DRB1*03:01, and DRB3*01:01 had higher rates (p adj. < 
0.005); no alleles had significantly lower rates (Figure 36). From a total of 9928 samples 
with genome-wide sequencing, paired normal and tumor somatic variant calling was 
available for 7776 samples. Whole exome sequencing required to infer HLA alleles was 
available for 7358 samples. Seven disease types contained less than 15 samples with these 
required data at the time of ingestion and were excluded from analysis: 
cholangiocarcinoma, kidney chromophobe, mesothelioma, ovarian serous 
cystadenocarcinoma, rectum adenocarcinoma, thymoma, uterine carcinosarcoma. 
Combining variant calling for these samples resulted in a total of 3,658,044 somatic 
variants, of which 29.8% were missense mutations of interest, resulting in a total of 
230,636,069 generated 8-15-mer peptides (Figure 19A). Integrating RNA expression data, 
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I found that 69.2% of these variants occured in genes that were at least minimally 
expressed in tumor samples and therefore potentially presented on MHC. Overall, after 
evaluating binding affinity, I identified 486,341 (0.25%) predicted MHC class I and 
638,107 (1.59%) predicted MHC class II neoepitopes from 7115 samples across 27 disease 
types (Table 9). This difference in percent neoepitopes is consistent with previous reports 
and the greater flexibility of peptide binding in the groove of MHC class II vs. MHC class 
I (Kreiter et al. 2015, Wang et al. 2008).  
As expected, I observed a close correlation between number of missense 
mutations and neoepitopes. Samples with the most to least number of missense 
mutations were found almost uniformly to have the most or least predicted MHC class I 
neoepitopes, with greater variability in the case of class II (Figure 19B, R-squared of 0.852 
and 0.452, respectively). When I stratified predicted neoepitopes by disease type, I found 
a wide distribution of neoepitope load (Figure 19C). The highest mean class I neoepitope 
load occurred in colon (291 ± 556), metastatic (321 ± 848) and primary (183 ± 222) 
melanoma and stomach (183 ± 296) disease types. Results for MHC class II neoepitopes 
were similar (colon: 1014 ± 3288, metastatic melanoma: 316 ± 513, primary melanoma: 
314 ± 531, stomach: 361 ± 864). HLA alleles possess variable binding stringency for 
peptide, likely determined by differences in binding groove characteristics across alleles. 
Accordingly, I note small but significant differences in rate of neoepitope generation 
across disease types for MHC class I, MHC class II or the combined rate (Figure 19D). 
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Disease types with the greatest deviations from the mean pan-cancer neoepitope rate for 
MHC class I were UVM (higher, p adj. = 0.083, see Figure 19C for abbreviations used 
throughout), TNBC (higher, p adj. = 0.118), and CESC (lower, p adj. = 0.083). For MHC 
class II, significant outliers were THCA (higher), PCPG (higher), ACC (lower), and 
PCPG (lower) (p adj. < 0.01).  
Recent reports suggest that genes commonly mutated in cancer may result in 
frequently reoccurring neoepitopes that could be targeted therapeutically. Targeting 
widely expressed neoepitopes derived from common driver mutations may be 
therapeutically advantageous even if these targets are only conserved across a small 
number of patients. To assess the feasibility of this, I determined the number of shared 
neoepitopes across all samples analyzed. I found a total of 1,872,298 peptides (< 1%) 
shared between at least two samples across all disease types, resulting in 2337 shared 
MHC class I neoepitopes and 4501 shared MHC class II neoepitopes (Figure 19E). While 
a sizable fraction of samples analyzed contained at least one such neoepitope (17% of 
samples for MHC class I, 70% of samples for MHC class II), only 11 neoepitopes were 
identified as shared between >5 samples across all disease types (Table 10). I found no 
significant enrichment for neoepitopes occurring in 373 genes identified to be 
significantly mutated in cancer, (Lawrence et al. 2013) and none of the 11 shared 
neoepitopes occurred in these genes. 
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Immune suppression associations with cytolytic index 
Rooney and colleagues have recently developed an RNA-based metric to assess 
cytolytic T-cell activity (cytolytic index) based on expression of Granzyme A (GZMA) 
and Perforin-1 (PRF1). This index accurately correlates with active CD8 cytolytic T-cells 
and other metrics of adaptive antitumor T cell immunity. I compared enrichment of 
cytolytic and immune suppression indices across TCGA disease types (Figure 20A). 
Consistent with previous findings reported in this dissertation for PDA, cytolytic T-cell 
activity was highly correlated with expression of immune suppression pathways (Figure 
20A, Figure 38). When I compared expression of individual genes comprising the 
immune suppression index across disease types, C10orf54 (VISTA), IDO1, ADORA2A 
(A2AR) and HAVCR2 had the highest expression across disease types compared to other 
molecules (Figure 20B, Figure 39). VISTA, IDO1 and other checkpoint genes may 
contribute to potential mechanisms of immune evasion (Restifo et al. 2016). TIGIT, 
PDCD1 (PD1), and CTLA4 are the genes within the immune suppression index with 
highest association with cytolytic index across TCGA. TIGIT contributes to an immune 
suppressive microenvironment by modulating dendritic cell cytokine production. 
Consistent with previous findings, (Rooney et al. 2015) the top genes associated with 
cytolytic index are CXCL8, CXCL10, and CASP8 (Figure 20C). Across all disease types 
examined, immune suppression index and normalized expression of CD8A were both 
highly correlated with cytolytic index (R-squared = 0.65, p adj. = 4.11e-7 and R-squared = 
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0.43, p adj. = 9.33d-6, respectively), suggesting that immune signatures are defined at the 
disease level and not at the sample level. There were no significant disease type outliers 
for the ratio of immune suppression index to cytolytic index, indicating that cytolytic 
activity and suppression increase proportionally across disease types from ‘cold’ to ‘hot’. 
Significant disease type outliers for ratio of CD8A expression to immune suppression 
index were DLBC (higher), SKCMm (higher), PRAD (lower), and LGG (lower) (p adj. < 
0.01). 
Immune environment predicts neoepitope load across human cancer 
I next assessed relationships between immune signatures and neoepitope load 
across disease types and patients. Overall, I found a significant correlation between mean 
neoepitope burden and mean CD8A expression or cytolytic index across disease types 
(Figure 21A-B). Significant disease type outliers for ratio of predicted MHC class I 
neoepitopes to CD8A expression were ACC, BLCA, and SKCMm, which are 
characterized by higher than average neoepitope load given mean CD8A expression 
compared to other disease types (p adj. < 0.01), and BRCA, CESC, DLBC, GBM, HNSC, 
KIRC, KIRP, LUAD, LUSC, PAAD, PCPG, PRAD, STAD, TGCT, THCA, TNBC, and 
UCS (p adj. < 0.01), characterized by lower load. For predicted MHC class II neoepitopes, 
disease types with higher than average ratio were ACC, BLCA, and LGG (p adj. < 0.01). 
Disease types with lower than average ratio were BRCA, CESC, DLBC, KIRP, LUAD, 
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LUSC, PAAD, PCPG, PRAD, TGCT, THCA, TNBC, and UCS (p adj. < 0.01). There were 
no significant outliers for ratios of cytolytic or immune suppression index to predicted 
MHC class I or MHC class II neoepitope load. Within each disease type I found 
significant correlations between neoepitope load and cytolytic index across samples in a 
minority of disease types; for MHC class I predictions, LGG, KIRC, SKCMm, and THCA, 
(Figure 40), as well as BRCA, TNBC, CESC, GBM, STAD, and THCA for MHC class II 
predictions (Figure 41). These data suggest that, in parallel to the relationship between 
cytolytic index and immune suppressive index, the relationship between cytolytic index 
and neoepitope load is best defined at the disease type level and is tightly coupled, as 
opposed to that between CD8A expression and neoepitope load. 
Taken together, these analysis shows a high degree of variability in neoepitope 
load and immune signature within and across tumor types. To best understand if 
associations between these variables can be discerned, I stratified samples within each 
tumor type on the basis of neoepitope load into neoepitope-high (NH) and neoepitope-
low (NL) cohorts (top and bottom decile within each disease type). I hypothesized that, 
while differences in immune environment on the basis of neoepitope load likely occur in 
a spectrum, these cohorts are most likely to represent distinct subclasses of disease for 
comparison. For instance, the size of the NH cohort roughly parallels that of tumor 
subtypes with evidently distinct immune environment, such as those responsive to 
checkpoint blockade. Similarly, many tumor types have a small, transcriptomically-
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identified subtype consisting of ‘immunogenic’ tumors (Bailey et al. 2016b, Cancer 
Genome Atlas Network 2015, Cancer Genome Atlas Research Network 2014, Guinney et 
al. 2015, Kandoth et al. 2013, Lehmann et al. 2011). I then used random forest machine 
learning analysis to determine whether immune or cancer related gene sets could 
distinguish these cohorts and if so, what gene set members were responsible for this 
predictive ability. Random forest analysis is a multivariable non-parametric ensemble 
partitioning tree method applicable to classification problems and can be used to 
determine the effect of multiple input variables on a response variable of interest 
(Breiman 2001, Chen & Ishwaran 2012, Ishwaran et al. 2014, Twyman-Saint Victor et al. 
2015). I use this methodology for two purposes: constructing a prediction rule for a 
response variable and then ranking input variables based on their contribution to 
predictiveness. Advantages of this approach over other methods are excellent 
discriminatory ability in high dimensional space, resistance to noise, missing data and 
overfitting, as well as built in error estimates (Boulesteix et al. 2012). I found both 
immune and cancer-related gene sets to predict classification of NH vs. NL for both class 
I and II neoepitopes. In agreement with findings reported in this dissertation that 
immune context is largely disease-specific, I noted low-to-modest pan-TCGA predictive 
ability for all gene sets examined, with T cell activity and T cell exhaustion gene sets 
performing best (Figure 21B-C, left bar plot). For predicted MHC class I and II 
neoepitopes, 17/25 and 14/27 disease types contained predictive models for the gene sets 
examined, respectively. T cell PD1-related, Reactome cytokine signaling, and T cell 
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exhaustion-related genes recently identified by (Schietinger et al. 2016) best distinguished 
NH vs. NL cohorts (Figure 21B-C, right heatmap). Figure 21D shows genes responsible 
for accurate prediction for selected models from Figure 21B. Genes were identified on the 
basis of minimal depth distance from the threshold for significance, a dimensionless 
statistic that measures variable predictiveness in tree-based models. Notably, immune 
suppression index genes were predictive of neoepitope load in both stomach 
adenocarcinoma and kidney renal clear cell carcinoma, but the gene set members 
important for this predictive ability were distinct, with IDO1 vs. PDCD1 ranked as the 
most predictive immune suppressive gene member, respectively. 
Superior survival of high predicted neoepitope groups 
Previous evidence suggests that increased load of immunogenic mutations is 
associated with significantly improved survival outcomes using samples from 512 patients 
across six disease types (Brown et al. 2014). This association existed when classifying 
neoepitopes to be any peptide with < 500nM binding affinity to MHC class I and also 
required samples to have high median HLA expression. No significant survival advantage 
was detected in high missense mutation burden patients or when fitting a model that 
contained an interaction between cancer type and immunogenic mutations. To extend 
this analysis, I stratified each disease type in TCGA into top or bottom deciles ranked by 
total missense mutations or neoepitopes and compared survival outcomes using available 
124 
 
TCGA clinical data. Age, gender and disease stage were not significantly imbalanced 
between cohorts and disease types with less than 15 samples or inadequately power were 
excluded from analysis. 
For 7 of 15 disease types examined, survival was not different between samples 
ranked in the top or bottom decile for each metric of interest (Figure 22A). For bladder 
adenocarcinoma, lung squamous cell carcinoma, metastatic melanoma, and stomach 
adenocarcinoma, samples ranked in the top decile of neoepitope metrics had significantly 
improved clinical outcomes (Figure 22A-B). Interestingly, a subset of disease types had 
improved survival when ranked in the bottom decile for neoepitope metrics. Samples in 
the bottom decile in glioma, head and neck squamous cell carcinoma, liver hepatocellular 
carcinoma, and sarcoma were associated with significantly improved survival. These data 
suggest that in disease types with high overall mutation rate, neoepitope load is associated 
with clinical utility and suggests the potential efficacy of targeting neoepitopes for 
therapeutic gain. 
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Discussion 
Sophisticated approaches continue to provide unprecedented resolution of the 
immunobiology of human cancer. In this study, I performed an extensive integrated 
analysis of the transcriptional and genetic landscape of PDA in the context of cytolytic 
immune activity in collaboration with Drs. Balli and Stanger. By stratifying patients with 
PDA based on a validated cytolytic gene expression signature (not previously applied to 
PDA), I identified a small subset of patients with evidence of prominent T cell reactivity. 
Beyond strong associations between cytolytic index and recently established 
transcriptional and genetic subtypes of this disease, these analyses revealed that low 
cytolytic activity tracked with increased genomic structural variation, most notably 
prominent and recurrent MYC amplifications and non-silent mutations and/or deletions 
in CDKN2A/B. Other distinct chromosomal aberrations were associated with cytolytic 
high PDA tumors. These data point to an underappreciated link between genomic 
alteration and immune activation in PDA, suggesting that genomic structural variation 
implicated in PDA progression may also fundamentally influence de novo or therapeutic 
antitumor immune activation, independently of host immune factors. 
I also report the first characterization of neoepitope load in PDA, finding in a 
large sample size encompassing the entire TCGA dataset for PDA that high cytolytic 
activity failed to correlate with increased load of nonsynonymous mutations or predicted 
neoepitopes. This is in striking contrast to the correlation between cytolytic index and 
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mutational burden in other tumor types such as lung and stomach adenocarcinoma, 
(Rooney et al. 2015) in which PD1 antibodies trigger clinically significant tumor 
regression. Indeed, recent studies have highlighted the primacy of tumor neoepitopes in T 
cell recognition of tumor cells, (Schumacher & Schreiber 2015) renewing interest in 
patient-specific approaches such as personalized vaccines (Vonderheide & Nathanson 
2013). Accordingly, the emerging paradigm is that neoepitope load determines sensitivity 
to immune checkpoint blockade (Rizvi et al. 2015, Snyder et al. 2014, Van Allen et al. 
2015). The lack of an association between neoepitope load and cytolytic index in PDA 
may reflect a tumor immunobiology that is distinct from that present in checkpoint 
blockade-sensitive tumors. Consequently, the assumption that neoepitope load is 
invariably associated with greater adaptive immunity may need to be reassessed, 
especially as it applies to patient selection in future PDA clinical trials. This lack of 
association in PDA may be due to extreme Kras-driven immunosuppression resulting in 
neoepitope-specific T cells that are not triggered, fail to expand, fail to infiltrate the 
tumor, or all of the above (Pylayeva-Gupta et al. 2012, Vonderheide 2014). Alternatively, 
the inherently low mutation rate seen in PDA, compared to lung and stomach 
adenocarcinoma may contribute to the lack of association between cytolytic reactivity and 
neoepitope load. These insights may explain the lack of clinical response to single-agent 
anti-PD1 therapy in patients with PDA and also indicate a need to vaccinate against 
tumor antigens and generate robust antitumor T cells in order to sensitize patients to 
checkpoint blockade. However, if intrinsic tumor suppression can be overcome by these 
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combinatorial methods, potent neoepitope-directed responses may yet be possible in the 
majority of PDA patients whose tumors contain dozens or more of these potential high-
affinity targets.  
 Our findings suggest that intrinsic oncogenic processes, rather than the 
availability of favorable immune targets, perhaps due to low mutation rate in PDA, may 
be the primary driver of immune activity in human PDA. MYC amplification is 
associated with decreased T cell infiltration in mouse models of hepatocellular carcinoma 
and human melanoma tumors with low cytolytic activity, suggesting that genomic 
alterations besides neoepitopes can modulate inflammatory response (Casey et al. 2016, 
Linsley et al. 2014). My comparison of the cytolytic index to established signatures of 
distinct PDA tumor and stroma types revealed a strong association with a gene signature 
representing a “normal stroma” phenotype (Moffitt et al. 2015), suggesting that the 
stromal microenvironment in PDA plays an important role in modulating inflammatory 
response. In PDA, oncogenic processes appear to enforce a state of immune privilege that 
precludes host T cell infiltration. Thus, immune checkpoint molecule upregulation in 
PDA may not be evidence of preceding T cell immunity, as is likely the case in melanoma 
and lung adenocarcinoma. 
I found that tumors with high cytolytic activity exhibited increased expression of 
multiple immune checkpoint genes such as CTLA4, TIGIT, TIM3, and VISTA. In 
contrast, PD-L1 expression was uniformly low. Whether therapeutic vaccines can 
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generate sufficient cytokine-producing T cells that infiltrate PDA tumors and upregulate 
PD-L1 remains to be seen in clinical trials; regardless, my data provide a rationale for 
prioritizing immune checkpoints other than only PD-L1/PD1 as therapeutic targets. 
While redundant suppressive mechanisms may undermine efforts to target any single 
immune checkpoint pathway, it may be possible to use expression profiling on a patient-
specific basis to accomplish “immune precision medicine.” In addition, the lack of 
immune activation in response to high neoepitope load additionally suggests that 
immune checkpoint blockade may be insufficient in a relatively low-mutation rate tumor 
type like PDA, and could be more effectively paired with immune-activating strategies 
that have shown promise is murine models (Soares et al. 2015, Vonderheide et al. 2013). 
In summary, my findings suggest that it will be important to look beyond standard 
neoepitope-based strategies for immunotherapy in PDA and to focus instead on other 
tumor-intrinsic features that render these tumors immune privileged. The extent to 
which this immunobiology characteristic of human PDA also manifests in other types of 
carcinoma requires further investigation. 
To determine how PDA fits in the larger landscape of neoepitopes across human 
cancer, I evaluated the high dimensional TCGA dataset, exploring relationships across 35 
diseases types and evaluating over 400 million peptides as potential neoepitopes. My 
analyses demonstrate that neoepitopes are abundant and tightly correlated with missense 
mutation load. Consistent with a previous report finding few shared neoepitopes in 
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patients with NSCLC, (Karasaki et al. 2015) I identify only a handful of neoepitopes 
shared between more than 5 samples out of more than 7000 samples analyzed, none of 
which occurred in genes significantly mutated in cancer (Lawrence et al. 2013). I find that 
neoepitope generation in human cancer is, as expected, a probabilistic process and 
therefore largely restricted to random passenger mutations expressed by tumors. 
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Tables 
 
Table 6. Patient information for TCGA PAAD dataset. 
See electronic supplementary materials. 
Table 7. GISTIC2.0 data for cytolytic TCGA PAAD dataset. 
See electronic supplementary materials. 
Table 8. MuSiC Genome significantly mutated gene (SMG) information for TCGA 
PAAD dataset. 
See electronic supplementary materials. 
Table 9. Pan-TCGA sample information, neoepitope load, and cytolytic index. 
See electronic supplementary materials. 
Table 10. Pan-TCGA shared neoepitopes. 
See electronic supplementary materials. 
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Figure 15. Stratification of human PDA based on cytolytic index. 
(A) Cytolytic index (geometric mean of expression of GZMA and PRF1 in 
transcripts per million (tpm)) across TCGA tumor types. Kidney renal clear cell 
carcinoma (KIRC, n = 606), lung adenocarcinoma (LUAD, n = 116), cervical squamous 
cell carcinoma and endocervical adenocarcinoma (CESC, n = 309), lung squamous cell 
carcinoma (LUSC, n = 553), pancreatic adenocarcinoma (PAAD, n = 134, red underline), 
stomach adenocarcinoma (STAD, n = 418), head and neck squamous cell carcinoma 
(HNSC, n = 566), colon adenocarcinoma (COAD, n = 328), skin cutaneous melanoma 
(SKCM, n = 105), bladder urothelial carcinoma (BLCA, n = 427), esophageal carcinoma 
(ESCA, n = 196), liver hepatocellular carcinoma (LIHC, n = 371), thyroid carcinoma 
(THCA, n = 572), ovarian serous cystadenocarcinoma (OV, n = 309), glioblastoma 
multiforme (GBM, n = 169), and prostate adenocarcinoma (PRAD, n = 555). Inset, 
cytolytic index between normal pancreas expression levels obtained from Genotype-
Tissue Expression (GTEx) project and TCGA PAAD. (B) Distribution of cytolytic genes 
within pancreatic adenocarcinoma. Gene set variation analysis (GSVA) signature scores 
for cytolytic index distinguished top decile (orange) and bottom quartile (green) samples 
for cytolytic-high (CYT High) and low (CYT Low) tumors, respectively.   
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Figure 16. Cytolytic index correlates with classifiers of PDA subtypes. 
(A) Hierarchical clustering of GSVA signature scores for gene programs defining 
PDA subtypes from (Bailey et al. 2016a, Collisson et al. 2011, Moffitt et al. 2015) (B) 
Distribution of GSVA signature scores for each PDA subtype program between cytolytic-
high and low tumors. ** = FDR adjusted P-values ≤ 0.05 and N.S. = Not statistically 
significant. (C) Hierarchical clustering of Moffitt Normal Stroma gene expression 
between cytolytic-high and low tumors showing enrichment in cytolytic-high tumors. 
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(D) Hierarchical clustering of Bailey GP1 Pancreatic Progenitor gene expression between 
cytolytic-high and low tumors showing enrichment in cytolytic-low tumors.  
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Figure 17. Low cytolytic index is associated with increased copy number alterations in 
Cytolytic Hot
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PDA. 
(A) Co-mutation plot showing significantly mutated genes (SMGs, FDR < 0.1) in 
cytolytic subsets in the PAAD dataset. Red boxes indicate mutation. SMGs that correlate 
with cytolytic subtypes (p < 0.05) are highlighted by green or orange circles in the left 
column. Genome MuSiC (v0.4) FDR p-values for SMGs are plotted in –log10 on the 
right. (B) Nonsynonymous mutation spectra across PDA cytolytic subsets. (C) KRAS 
mutation types across PAAD dataset and association with cytolytic index, showing no 
statistically significant correlation between KRAS mutations and cytolytic subsets. (D) 
GISTIC2.0 analysis identified recurrent somatic copy number alterations (SCNA) in 
cytolytic-low tumors. Recurrent amplifications at 8q24.21 (MYC), 1p12 (NOTCH2), 
8p11.22 (FGFR1), and deletions at 9p21.3 (CDKN2A/B), 18q21.2 (SMAD4) in CYT low 
tumors. (E) Total SCNA were calculated for each TCGA PAAD patient and were 
significantly increased in cytolytic-low tumors (Mann-Whitney). (F) Co-mutation plot of 
copy number alterations and non-silent SNVs/INDELs in genes amplified or lost in 
cytolytic-low PDA tumors. 
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Figure 18. Inhibitory checkpoint molecules, but not neoepitope load, are associated with 
cytolytic index in PDA. 
(A) Local regression curves (Spearman rank correlation) between cytolytic index 
and total mutation count and boxplot distributions between cytolytic subsets (Mann-
Whitney). (B) Local regression curves and boxplot distributions between cytolytic subsets 
for cytolytic index and total MHC class I neoepitopes (50nM predicted binding affinity) 
and (C) cytolytic index and number of mutations generating ≥ 1 neoepitopes to MHC 
class I. (D) Local regression curves and boxplot distributions between cytolytic subsets for 
cytolytic index and total MHC class II neoepitopes (<1% rank) and (E) cytolytic index 
and number of mutations generating ≥ 1 neoepitopes to MHC class II. (F) Differentially 
expressed chemokines, cytokines, and inhibitory checkpoint molecules between cytolytic-
high (top decile) and low (bottom quantile) samples across TCGA. Fold change between 
subtypes indicated by color. Size of circle indicates statistical significance (-
log10(Adjusted P value)). Arrow and box indicate no differential expression of PD-L1 
(CD274) in between cytolytic subtypes in TCGA PAAD dataset. (G) Distribution of 
inhibitory immune checkpoint index (geometric mean of TPM values) across PAAD 
TCGA. Checkpoint molecules: CD274 (PD-L1), IDO2, PDCD1LG2 (PD-L2), CTLA4, 
IDO1, ADORA2A (A2AR), LAG3, PDCD1 (PD1), TIGIT, HAVCR2 (TIM3), VISTA 
(C10orf54), VTCN1 (B7-H4). (H) Local regression curve showing statistical significant 
relationship between cytolytic index and inhibitory immune checkpoint index in PDA 
(Spearman rank correlation). (I) Expression of differentially expressed Treg markers in 
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PDA subsets. (J) Expression of differentially expressed inhibitory checkpoint molecules. 
N.S = not statistically significant, ** = FDR adjusted P-values < 0.1. 
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Figure 19. Neoepitope landscape in human cancer. 
(A) Pipeline overview of data types (grey), intermediate pipeline steps (tan), 
important computational steps (orange) and results (red). See Figure 34 for a detailed 
pipeline. (B) Parallel coordinate plot showing relationship between frequency of 
mutations, MHC class I neoepitopes, and MHC class II neoepitopes in all samples 
analyzed. Lines are individual samples in the top (red) or bottom (blue) decile by MHC 
class I neoepitope load and are normalized on each node. (C) Summary of missense 
mutations, predicted MHC class I neoepitopes (<50nM affinity), predicted MHC class II 
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neoepitopes (<1% rank) and cytolytic index (geometric mean GZMA and PRF1 
normalized expression) by disease type. Disease types are ordered from top to bottom by 
mean missense mutations. Sample numbers shown are for MHC class I neoepitope load. 
See Figure 37 for individual samples by disease type. (D) Predicted neoepitope rate across 
all disease types analyzed. Blue box and line indicate the 75th to 25th percentile and 
median, respectively. Disease subtypes are ordered from left to right by mean. P value is 
by ANOVA. (E) Shared MHC class I and II neoepitopes across all samples analyzed. 
Neoepitopes were considered duplicates across samples if the same peptide sequence met 
neoepitope criteria for sample-specific HLA. Calculation of duplicated peptides and 
neoepitopes is independent of sample HLA allele.  
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Figure 20. Immune suppression associations with cytolytic index. 
(A) Cytolytic index (blue) and immune suppression index (orange) across all 
disease types analyzed. Cytolytic index is expressed as the gene set variation analysis 
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(GSVA) score of normalized expression of genes GZMA and PRF1. Immune suppression 
index is the gene set variation analysis (GSVA) score of normalized expression for genes 
ADORA2A (A2AR), CD274 (PD-L1), PDCD1 (PD1), CTLA4, HAVCR2 (TIM3), IDO1, 
IDO2, PDCD1LG2 (PD-L2), TIGIT, VISTA (C10orf54), and VTCN1 (B7-H4). Box and 
line indicate the 75th to 25th percentile and median, respectively. Disease subtypes are 
ordered from left to right by mean cytolytic index. P value is by ANOVA. (B) Heatmap of 
normalized log10 immune suppression index member gene expression across disease 
types. Columns and rows are unscaled and ordered by hierarchical clustering. (C) Mean 
immune suppression (light blue) and overall top (dark blue) gene associations with 
cytolytic index across all disease types analyzed. (D-E) Mean immune suppression index 
(D) or CD8A normalized expression (E) vs. cytolytic index by disease type as labeled. R-
squared values are for linear regression and P values are for Spearman’s rho. Dotted line 
is Bonferroni-adjusted cutoff for significance.  
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Figure 21. Immune environment predicts neoepitope load. 
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(A-B) Mean MHC class I and II predicted neoepitope load vs. CD8A expression 
(A) and cytolytic index (B), by disease type as labeled. See Figure 40 and Figure 41 for 
sample scatterplots by disease type. R-squared values are for linear regression and P 
values are for Spearman’s rho. (C-D) Predictability of top immune-related gene sets for 
MHC class I neoepitope load (C) and MHC class II neoepitope load (D) across all tumor 
types (left, bar plot) and by disease type (right, heatmap). Classification models were for 
the top and bottom decile ranked within each disease subtype. Relative Brier score is the 
normalized Brier score relative to negative control for the re-fit forest after top variable 
selection, averaged across bootstrap iterations. A relative Brier score equal to 1 denotes 
equivalency to negative control (equal to random guessing) and a relative Brier score 
equal to 0.9 denotes a 10% improvement over negative control. A Brier score equal to 0 
denotes perfect predictive ability. Barplot is for all disease types. Heatmap is unscaled and 
ordered form left to right alphabetically. (E) Minimal depth plots for selected predicted 
MHC class I neoepitope models from (C). Listed genes are top variables from the 
analyzed gene set used to predict high vs. low class membership and are ranked from top 
to bottom by mean minimal depth. Minimal depth is a measure of variable importance 
derived from individual trees in the forest. Smaller values indicate greater importance and 
absolute values are model-specific. Minimal depth is defined as the distance between the 
root node of a tree in the forest and the closest maximal subtree for the indicated gene. 
Dotted line indicates minimal depth threshold of significance, defined as 1 standard error 
below the mean across all model variables.
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Figure 22. Superior survival of high predicted neoepitope groups. 
(A) Summary of Kaplan-Meier p values for missense mutations or the indicated 
neoepitope class across all disease types analyzed. Comparison is between high (red) and 
low (blue) neoepitope load patients, defined as the top and bottom decile, respectively. P 
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values highlighted in yellow are significant. Disease types with low sample number are 
excluded. (B) Selected Kaplan-Meier curves for the indicated disease subtypes showing 
survival difference between high (red) and low (blue) neoepitope load patients. Tick 
marks denote the last time survival status was known for living patients. 
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Figure 23. Cumulative distribution of cytolytic index between PAAD and STAD cohorts. 
Cumulative density (left) and cumulative frequency (right) of the cytolytic index 
between PDA (PAAD) and stomach adenocarcinoma (STAD) cohorts in TCGA. PDA 
has a much smaller distribution in comparison with STAD (Kolmogorov-Smirnov test).  
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Figure 24. Enrichment of selected immune related gene sets in cytolytic-high PDA 
tumors. 
Cytolytic-high tumors show increase enrichment of gene sets from activated, 
cytolytic CD8 T cell populations (Duraiswamy et al. 2014, Parish et al. 2009). 
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Figure 25. Enrichment of immune related gene sets in cytolytic-high PDA tumors 
Gene set variation analysis (GSVA) of known immune related gene sets show 
statistically significant increase in tumors identified as cytolytic-high based on expression 
GZMA and PRF1.   
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Figure 26. Cytolytic index associates strongly with expression of Immunome gene sets. 
(A) GSVA scores for gene sets comprising 28 immune cell types identified 
previously. (Immunome, (Bindea et al. 2013)) Cytolytic high and low tumors are 
designated by orange and dark green boxes, respectively. (B) GSVA of gene sets related to 
Tight junctions, Argiddnine/Proline Metabolism, Cholesterol/Steroid synthesis, and 
glucose metabolism from the REACTOME (R) and KEGG (K) databases. (C) GSVA of 
gene sets related to Cholesterol/Steroid synthesis, and glucose metabolism from the 
REACTOME and KEGG databases.  
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Figure 27. Expression of copy number alteration-associated and MYC target genes are 
(A) Gene set enrichment analysis (GSEA) of genes whose expression in pancreatic 
tumor correlated with copy number gains. (Aguirre et al. 2004). (B) GSEA of known 
MYC target genes (Zeller et al. 2003). ES = Enrichment Score, NES = Normalized 
Enrichment Score, FDR = False discovery rate.  
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Tumor purity estimates for TCGA PAAD do not correlate with total mutation 
count (top left), total copy number events (top right), type I neoepitopes (bottom left), 
and type II neoepitopes (bottom right).  
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Figure 28. Tumor cellularity/purity estimates do not correlate with mutational load. 
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Figure 29. Tumor purity estimates for PDA, stomach adenocarcionma (STAD) and lung 
adenocarcinoma (LUAD). 
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Figure 30. No difference in tumor cellularity or purity between cytolytic subtypes in 
TCGA PAAD cohort. 
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Figure 31. Cytolytic subtypes associate with neoepitope load in stomach adenocarcionma 
(STAD) and lung adenocarcinoma (LUAD). 
Figure S9.
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Figure 32. Neoepitope burden does not differ across PDA subtypes. 
(A) Hierarchical clustering of TCGA PAAD dataset using subtype classifiers from 
(Moffitt et al. 2015) (left) and (Bai et al. 2015) (right) and association with cytolytic 
subtypes. (B) Mutation and neoepitope load as a function of Moffitt subtype classification 
of TCGA PAAD. Statistical enrichment of total mutation count between Classical and 
Normal Stroma (one-way ANOVA, Tukey’s post hoc test for multiple comparisons). (C) 
Same B except using Bailey subtype classification of TCGA PAAD.  
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Figure 33. Correlation plots of individual Immune suppression index versus cytolytic 
index. 
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Figure 34. Neoepitope analysis pipeline. 
Schematic of neoepitope analysis pipeline showing TCGA datasets (grey), pipeline steps 
(tan), MHC affinity prediction (orange), results (red) and analysis (green). The 
Neoepitopes R package source code is freely available can be obtained from GitHub 
(https://github.com/andrewrech/Neoepitopes).
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Figure 35. TCGA sample cancer DNA fraction. 
A. Cancer DNA fraction across all disease types analyzed. B. Relationship between 
number of missense mutations and cancer DNA fraction across all samples analyzed. R-
squared values are for linear regression and P values are for Spearman’s rho. Cancer DNA 
fraction was determined using ABSOLUTE.(Carter et al. 2012)  
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Figure 36. TCGA HLA types. 
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(A) Predicted MHC class I (left) and class II (right) HLA types for all samples 
analyzed. The area of the box is proportional to the occurrence of the indicated HLA 
allele across all samples analyzed. (B) Observed neoepitope rate (predicted neoepitopes / 
total predictions) across all HLA alleles analyzed. Blue box and line indicate the 75th to 
25th percentile and median, respectively.  
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Figure 37. Missense mutations and neoepitopes across disease types. 
164 
 
Missense mutations (A), MHC class I neoepitopes (B), MHC class II neoepitopes 
(C) across all disease types analyzed. Blue box and line indicate the 75th to 25th percentile 
and median, respectively. Disease subtypes are ordered from left to right by mean. P 
values are by ANOVA.  
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Figure 38. Immune suppression index member gene expression across selected disease 
types. 
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Columns (samples) and rows are unscaled and ordered by hierarchical clustering. 
BRCA: Breast non-TN, TNBC: Breast TN, LUAD: Lung adeno., OV: Ovarian, PAAD: 
Pancreatic, PRAD: Prostate, SKCMm: Melan. Met.  
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Figure 39. Immune suppression index vs. cytolytic index. 
Mean class I neoepitope load by disease type as labeled. R-squared values are for 
linear regression and P values are for Spearman’s rho. 
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Figure 40. Predicted neoepitopes (class I) vs. cytolytic index. 
Predicted MHC class I neoepitopes vs. cytolytic index across all samples for the 
indicated disease type. R- squared values are for linear regression and P values are for 
Spearman’s rho. Diseases types are ordered alphabetically. 
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Figure 41. Predicted classic neoepitope (class II) vs. cytolytic index. 
Predicted MHC class II neoepitopes vs. cytolytic index across all samples for the 
indicated disease type. R- squared values are for linear regression and P values are for 
Spearman’s rho. Diseases types are ordered alphabetically.  
170 
 
CHAPTER 5 – Discussion 
Research over the past two decades demonstrates that the immune system plays a 
dual role in most forms of cancer. The immune system can suppress tumor growth for 
long periods of time by eliminating tumor cells, but also promote growth by selecting for 
resistant tumor cells or establishing a hospitable tumor microenvironment. These 
protective and deleterious effects are the basis of the cancer immunoediting hypothesis, in 
which the immune system quantitatively and qualitatively impacts tumor development, at 
first eliminating tumor cells but eventually becoming ineffective, leading to tumor escape 
(Schreiber et al. 2011). Our expanded understanding of the immune system’s role in 
cancer has led to refined attempts to control cancer via immunotherapy. In most 
experimental systems, effective cancer immunotherapy requires CD8 effector T cells, as 
confirmed by hallmark murine studies (DuPage et al. 2012, Matsushita et al. 2012). 
Indeed, the quantity, quality and distribution of CD8 effector T cells correlate positively 
with patient survival (Erdag et al. 2012, Naito et al. 1998, van Houdt et al. 2008). The 
distribution of regulatory T cells that suppress CD8 effector T cells correlates negatively 
with patient survival (Curiel et al. 2004, Knol et al. 2011) and it is increasingly apparent 
that the escape phase includes tumor-instructed immunosuppression that thwarts 
productive antitumor immunity. Recent breakthroughs, notably the success of immune 
checkpoint blockade in patients with metastatic melanoma, (Hodi et al. 2010, Topalian et 
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al. 2012) demonstrate the relevance of understanding such resistance pathways and 
broader determinants of immunity. 
Immune vs. tumor origins of therapeutic resistance 
In work investigating the combination of radiation and immune checkpoint 
blockade (Chapter 3, page 63), I found that RT enhances the diversity of the T cell 
receptor (TCR) repertoire of intratumoral T cells and anti-CTLA4 predominantly inhibits 
T regulatory cells (regulatory T cells) to increase the CD8 T cell to Treg (CD8/Treg) ratio. 
Together, anti-CTLA4 promotes expansion of T cells, while RT shapes the TCR 
repertoire of the expanded peripheral clones. Addition of PD-L1 blockade reverses T cell 
exhaustion to mitigate depression in the CD8/Treg ratio and further encourages oligo-
clonal T cell expansion. Thus, PD-L1 on melanoma cells allows tumors to escape anti-
CTLA4-based therapy, and the combination of RT, anti-CTLA4, and anti-PD-L1 
promotes response and immunity through distinct mechanisms. 
In contrast to my work demonstrating a tumor cell-intrinsic mechanism of PD-L1 
upregulation in melanoma, recent work also in melanoma shows that the induction of 
immune checkpoint pathways is a consequence of CD8 T cell infiltration (Spranger et al. 
2013). In this melanoma model, mechanistic studies demonstrated that upregulation of 
PD-L1 by tumor cells was dependent on the presence of CD8 T cells and interferon-γ – a 
172 
 
negative feedback loop intrinsic to immune activation and independent of oncogene 
signaling. Of course, oncogene-driven vs. T cell-driven regulation of tumor PD-L1 are 
not mutually exclusive, and future studies may resolve the contribution of each 
mechanism in these malignancies. In a different murine melanoma model, previous work 
has already demonstrated a role for the EGFR pathway in immune suppression via 
upregulation of the cytokine CCL27 (Pivarcsi et al. 2007). Nevertheless, there may be 
important differences between tumors expressing PD-L1 due to oncogenes and those in 
which PD-L1 is induced due to the infiltration of antitumor T cells. The former is less 
likely to have undergone selective pressure exerted by the immune system, and may 
therefore respond more favorably to additional immune therapies. These investigations 
also generate hypotheses for how to identify patients who are likely to respond to PD1 
blocking antibodies. For instance, I can speculate that EGFR-driven NSCLC tumors may 
benefit from PD1 blockade regardless of preexisting immune infiltrate. Alternatively, 
melanomas harboring a T cell-inflamed tumor microenvironment may respond 
regardless of driving mutations such as BRAF, the status of which does not appear to 
predict response to anti-CTLA4.  
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Determinants of adaptive immunity in pancreatic ductal adenocarcinoma 
Pancreatic ductal adenocarcinoma (PDA) is a difficult clinical problem, with poor 
response to therapy including near universal failure of single-agent immune checkpoint 
blockade antibodies. This biology is investigated in Chapter 4 (page ). To understand the 
features that might make some tumors more responsive to immunotherapy, I used 
publically available expression data from 134 primary resection PDA samples from 
TCGA to stratify patients according to a cytolytic T-cell activity expression index. I 
correlated cytolytic immune activity with mutational, structural and neoepitope features 
of the tumor. I found that high cytolytic activity in PDA does not correlate with increased 
neoepitope burden. Rather, tumor-intrinsic characteristics such as MYC and NOTCH2 
amplifications and recurrent deletions and mutations at CDKN2A/B are linked to the 
status of intratumoral immune activation. High cytolytic activity is associated with 
increased expression of multiple immune checkpoints (with the notable exception of PD-
L1).  
Our emerging understanding suggests that rather than being linked to mutation 
burden or neoepitope load, immune activation indices in PDA are linked to genomic 
alterations, suggesting that intrinsic oncogenic processes drive immune activity in human 
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PDA. My data support the utility of combining genomic and immune profiling for a 
comprehensive understanding of immune activation in PDA. This approach may help 
guide the development of effective immune therapy in PDA and other immune therapy-
refractory cancers. Furthermore, these data highlight the potential importance of immune 
checkpoints other than PD-L1/PD1 as therapeutic targets in this lethal disease. 
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The landscape of neoepitopes in human cancer 
Chapter 4 (page 103) builds on previous work by others (Brown et al. 2014, 
Rooney et al. 2015) and my own initial study of PDA by expanding analysis of 
neoepitopes to MHC class I and II types across 9928 human cancer samples belonging to 
35 solid tumor types. I evaluated over 400 million peptides generated from over 1 million 
missense mutations and then characterized multiple immune indices, immune- and 
cancer-related gene sets, and gene mutational status for associations with neoepitope 
load. I also assessed the overall characteristics of neoepitope load, type and quality in 
human cancer at the global level and employed machine learning to understand complex 
relationships in these data and build predictive models. Due to the probabilistic nature of 
neoepitope generation and high MHC allele diversity in humans, I find there are nearly 
zero neoepitopes shared across patients in human cancer at frequencies amenable to 
therapeutic targeting. Though previous reports have found deviations in the expected vs. 
observed number of neoepitopes in some disease types, (Rooney et al. 2015) I note few 
meaningful differences in my analysis. Higher resolution exome sequencing of human 
tumors, improved prediction tools, and appreciation of newly-identified sources of 
neoepitopes (Liepe et al. 2016) may be required to confirm evidence of population-scale 
immunoediting. 
Our results suggest that predicted neoepitope load correlates closely with rate of 
missense mutations, in agreement with previous findings (Rooney et al. 2015). Recent 
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work has identified a non-synonymous mutation cutoff of 192, based on published 
response rates to checkpoint inhibitors, and hypothesized that this discriminates patients 
likely to respond to checkpoint blockade. This includes 30% of bladder, colon, gastric and 
endometrial cancers. I note that while these patients may be more likely to respond, a 
small number of neoepitopes can drive therapeutically effective antitumor T cell 
responses, (Linnemann et al. 2013, Lu et al. 2013, Matsushita et al. 2012, Robbins et al. 
2013) and I find few strong correlations within these tumor types between cytolytic 
activity and missense mutation or neoepitope load despite large variability in these 
metrics across samples within each disease type. This suggests that spontaneous 
immunity in primary adenocarcinomas is unlikely to be limited by a critical neoepitope 
threshold, consistent with a recently published report (Spranger et al. 2016).  
Accordingly, the abundance of neoepitopes across solid tumors in my analysis 
suggests that immunotherapies capable of improving T cell priming, infiltration or 
effector function have at least dozens of ‘immunologically visible’ targets to act upon in 
nearly all solid human tumors. This is especially true given that technical limitations in 
exome sequencing depth and tumor sample purity, as well as ample additional sources of 
neoepitopes such as frameshift mutations and gene fusions, (Maby et al. 2016, Zhang et 
al. 2016) imply that my analyses necessarily underreport absolute neoepitope load. Thus, 
the potential for T cell immunity with checkpoint blockade or other strategies is unlikely 
to be limited to high mutation load patients or disease types on the basis of available T 
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cell targets. Additionally, the effect of greater neoepitope load on likelihood of response is 
probably disease type-specific. For instance, anti-PD1 may be effective therapy in colon 
adenocarcinoma patients whose tumors harbor microsatellite instability, (Llosa et al. 
2015) in contrast to the majority of colon cancer patients. Yet my results suggest a strong 
correlation between immunity and neoepitope load in kidney renal clear cell carcinoma, 
and a landmark study has shown that these patients respond to immune checkpoint 
blockade despite a median neoepitope load considerably lower than that in colon 
adenocarcinoma (Brahmer et al. 2012, Topalian et al. 2012).  
An alternative explanation of the varied association between neoepitope load and 
responses to checkpoint blockade across tumor types is that underlying genetic subtypes 
with greater DNA damage are also characterized by distinct immune profiles, a subset of 
which may be amenable to checkpoint blockade. For example, several recent reports have 
identified distinct melanoma or pancreatic adenocarcinoma molecular subtypes 
associated with immune activity, yet the underlying genetic alternations that comprise 
these subtypes differ substantially (Bailey et al. 2016b, Cancer Genome Atlas Network 
2015). My findings of diverse predictive ability of immune- and cancer-related gene sets 
for neoepitope load across disease and neoepitope type underscore this heterogeneity. 
Beyond first approximation correlations with CD8 T cell infiltration or other broad, 
previously described metrics, the dynamics of adaptive immune activity with respect to 
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neoepitope load or patient outcome must be contextualized in a disease type-specific 
manner. 
The diverse pattern of immune suppressive molecules observed at the disease type 
level further suggest that tailoring the blockade of inhibitory pathways in a disease or 
patient-specific manner, rather than focusing on overall mutational and/or neoepitope 
burden, is likely required to overcome suppressive barriers within the tumor 
microenvironment. My data indicate that tumor-specific neoepitopes alone are not 
sufficient to elicit a positive immune response: several disease types with high mutation 
rates were not associated with improved survival outcomes in patients belonging to the 
top decile by neoepitope load. In fact, several disease types have negative association 
between survival outcome and high neoepitope/mutation load. I have shown in Chapter 4 
(page 103) that cytolytic response can be disconnected from elevated neoepitope load in 
pancreatic ductal adenocarcinoma (Balli et al. 2016). I find here that expression of 
immune suppressive index gene members is heterogeneous across TCGA disease types. 
Thus, my data suggest that immune- or tumor-intrinsic sequelae of increased cytolytic 
activity within the tumor microenvironment, that vary dramatically across human cancer, 
determine potential neoepitope immunogenicity. My finding that cytolytic index, but not 
overall CD8A expression, is coupled to immune suppression index and neoepitope load at 
the disease level across 35 human cancer types suggests that immune-intrinsic regulation 
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tightly controls cytolytic activity in the tumor microenvironment regardless of tumor 
etiology.
180 
CHAPTER 6 –Future directions 
Combinatorial radiotherapy and immunotherapy 
More than half of cancer patients receive RT during the course of treatment 
(Delaney et al. 2005). RT achieves local control of disease and improvements in survival 
in lung, prostate, and head and neck cancer and is used palliatively in many other disease 
types. Yet a major limitation of RT, and the primary mechanism of treatment resistance, 
is disease reoccurrence outside the treatment field. For instance, most pancreatic cancer 
patients, regardless of whether their primary tumor is resectable, develop distant 
metastases and die within two years of diagnosis (Hidalgo 2010). My data add to 
increasing evidence that tumor-intrinsic pathways alter the tumor microenvironment to 
promote immune escape. Cellular immune responses to radiation and adaptive immunity 
intersect at the level of proinflammatory signals, antigen-presenting cell maturation, T 
cell priming and tumor cell recognition. Dissecting the crosstalk between oncogene-
driven networks of immune suppression and the dynamic regulation of tumor-
infiltrating T cells will no doubt be a critical area of investigation in the future. In 
particular, whether immune modalities can limit abscopal reoccurrence, and the extent of 
overlap between tumor and immune-intrinsic resistance pathways to RT and immune-
modulating antibodies, will require careful mechanistic insight. The PDA tumor 
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microenvironment is a profoundly immune suppressive one, where immune resistance 
similarly overlaps with pathways of radioresistance. Successful combinatorial therapy in 
PDA will require a greater understanding of these intersection points, especially in regard 
to regulatory T cells and myeloid-derived suppressor cells that are shown to facilitate 
pancreatic immune tolerance.  
A critical additional future direction is how radiation may augment the creation 
or processing of tumor rejection antigens; unaccounted for neoantigens that arise after 
RT may play a crucial role in tumor rejection, especially in solid adenocarcinomas with 
the lowest baseline availability of neoantigens. Radiotherapy has been shown to induce T 
cell responses to peptides that are upregulated in response to radiation-induced cell 
damage, (Reits et al. 2006) which occurs due to increased protein translation induced by 
activation of the mammalian target of rapamycin pathway. The extent that this, or other 
mechanisms by which RT directly contributes to loss of acquired immune privilege, are 
operative in human cancer has not been investigated. Future work should determine the 
relative importance of these factors vs. indirect effects of RT on proinflammatory milieu, 
which will have implications for therapy design. 
Future clinical trials will need to carefully investigate a role for RT with 
combinatorial immune checkpoint blockade and other immune-modulating antibodies. 
First, RT may enhance what is in some cases, notably combinatorial therapy with anti-
CTLA4 and anti-PD1, an already severe toxicity profile (Silk et al. 2013). Second, immune 
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checkpoint blockade results in a unique pattern of response in which tumor T cell 
infiltration may appear radiologically as progression in some patients, necessitating use of 
novel response criteria that must be factored into design of clinical trials incorporating 
RT (Bohnsack et al. 2014, Wolchok et al. 2009). Third, due to the risk of inducing 
clinically significant lymphopenia that may negatively impact antitumor 
responses,(Grossman et al. 2015) an important design criteria will be choice of RT 
approach and regimen. The tolerance of circulating lymphocytes to radiation is 
dependent on fractionation and irradiated surface volume, (Yovino et al. 2013) therefore 
stereotactic delivery over fewer fractions to smaller tissue volumes may be preferable. 
Preclinical models have yielded conflicting data regarding whether hypofractionated 
protocols are required or yield superior results as an immune adjuvant. Clinically, an 
initial retrospective analysis of melanoma patients with brain metastases treated with a 
single high-dose fraction vs. conventional RT suggests the former may be superior, (Silk 
et al. 2013) and many ongoing clinical trials with diverse fractionation schemes may 
confirm this (Spiotto et al. 2016). A related basic question is whether irradiation of all vs. 
part of a tumor is required for optimal immunity. In summary, it is likely the precise 
nature of RT delivery will have profound impact immune biology and treatment efficacy, 
warranting a systematized approach to investigation that does not currently exist. 
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Emerging classes of neoepitopes 
I have established that predicted neoepitope formation in human cancer is 
essentially a probabilistic process. Yet it is possible that certain classes of neoepitopes are 
more advantageous than others as targets for therapeutic gain or as correlative markers to 
understand immunity. For instance, neoepitopes derived from mutations in oncogenic 
driver genes may be important targets of adaptive antitumor immunity due to the 
resistance to selective pressure these offer. Additionally, gene mutation status, especially 
mutations resulting in greater genomic instability or deficiency in DNA repair, may 
correlate with neoepitope load or response to immune therapies that augment 
neoepitope-directed T cell responses.  
Recent investigations have led to additional factors to consider when identifying 
and prioritizing neoepitopes. To date, essentially all neoepitope analysis pipelines, 
including my own, have relied on missense mutations as the single source of somatic 
differences that could result in novel peptides for which no self-tolerance likely exists. 
These are chosen because identification is computationally straightforward and error-
resistant; however, this is an obvious simplification of the genomic variation present in 
tumors that can result in novel peptides. Next generation neoepitope prediction pipelines 
will also consider gene fusions, which may be of particular importance in tumor types 
with very few somatic missense mutations such as many pediatric tumors. Excellent tools 
exist for identifying gene fusions and predicting which lead to fusion peptides that could 
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be processed and presented by MHC, (Kumar et al. 2016) though higher quality RNA 
sequencing than is generally available in large databases of tumor samples may be 
required for accurate analysis. 
Prioritizing neoepitopes by likelihood of immunogenicity, for experimental 
validation or inclusion in peptide vaccines, is a major future challenge. Currently, despite 
significant enrichment by computational methods for high-affinity peptides that generate 
T cell reactivity (Castle et al. 2012), only a minority of identified neoepitopes can be 
validated to generate immunity in vivo (McGranahan et al. 2016). An additional factor to 
consider for prioritization in the future is neoepitope clonality, as recent work has found 
that highly clonal neoepitopes are associated with an inflamed tumor microenvironment 
in lung adenocarcinoma (McGranahan et al. 2016). PD-L1 and IL-6 were significantly 
upregulated in tumors with low intratumoral heterogeneity and high neoepitope clonality 
in this analysis. An enticing hypothesis is that high neoepitope clonality can be used as 
selection criteria across human cancer. Clonal neoepitopes are more widely shared across 
tumor cells and may therefore be particularly advantageous for adoptive therapy 
approaches that subject a handful immune targets to extreme selective pressure (Fisher et 
al. 2013).  
Many neoepitopes have wildtype counterparts that also bind MHC class I with 
high-affinity. In these cases, unless missense mutations occur on TCR contact residues or 
substantially alter peptide structural characteristics, T cells may be similarly reactive 
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against normal and mutant peptides and thus subjected to central tolerance, a paradigm 
that does not exist in the case of foreign antigens used to establish affinity criteria for 
peptides to MHC. Differential agretopicity (DAI) expresses the degree to which the 
determinants of peptide binding to MHC class I or II differ due to the presence of a 
missense mutation. Previous work has demonstrated that selection of neoepitopes on the 
basis of high DAI resulted in a substantially improved rate of experimentally-validated 
tumor-protective epitopes (Duan et al. 2014). To determine differential agretopicity and 
identify peptides with high DAI, I could select mutant peptides that at least minimally 
bind MHC and then compare the binding affinity of these peptides to their normal 
counterpart. Because these selection criteria differ substantially from those for classic 
neoepitopes, I would expect these classes of neoepitopes to be largely non-overlapping 
sets. Indeed, previous work has found that classic vs. high DAI neoepitopes differ 
substantially in amino acid composition and mutant amino acid positon within the MHC 
binding groove (Duan et al. 2014). Thus, human cancer types demonstrated to have 
different mutation profiles, (Alexandrov et al. 2013, Ciriello et al. 2013) due to distinct 
mechanisms of genomic instability, may differ substantially in the availability of classic vs. 
high DAI neoepitopes for targeting. 
Taken together, my identification of MHC class I and class II neoepitopes imply 
that a larger than currently appreciated pool of potential neoepitopes exists across human 
tumor types. It will be important for future studies to investigate the relative importance 
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of these and emerging neoepitope classes. Some recent evidence already suggests MHC 
class II and high DAI neoepitopes are important. Due to the relatively high promiscuity 
of peptide binding in the groove of MHC class II vs. class I, I found that on average, 
missense mutations are more likely to generate MHC class II neoepitopes. Kreiter et al. 
recently identified MHC class II neoepitopes capable of driving therapeutic responses in 
murine tumor models, (Kreiter et al. 2015) and mutation-specific CD4 T cells recognize 
neoepitopes and can mediate tumor regression in humans (Linnemann et al. 2015, Tran 
et al. 2014). Whether broad class II-restricted T cell responses exist in human cancer and 
can be augmented therapeutically remains to be determined, and my results indicate that, 
similar to MHC class I, immune activity against MHC class II neoepitopes is unlikely to 
be limited on the basis of prevalence in virtually any solid tumor type. 
Recent findings are also consistent with an important role for high DAI 
neoepitopes, identified on the basis of improved MHC binding vs. normal sequence 
counterparts, in mice and humans. In 2012, one of the first investigations of neoepitopes 
identified many missense mutation-containing B16-F10 melanoma peptides based on 
predicted MHC class I affinity, subsequently experimentally verifying the 
immunogenicity of these peptides (Castle et al. 2012). 11/13 reactive mutant peptides 
identified were found to have normal counterparts with equal or less reactivity, 
suggesting that in the B16-F10 model, immunogenic mutations generally do not result in 
substantial changes in critical TCR-facing amino positions. Many of these normal 
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peptides presumably bypassed central tolerance by not binding strongly enough to class I 
MHC, as hypothesized. In humans, three validated neoepitopes in NSCLC patients all 
had higher predicted binding for mutant vs. normal peptide.(McGranahan et al. 2016) In 
1 out of 3 cases, the generating missense mutation resulted in an anchor position change 
and would therefore be classified as a high DAI peptide. Thus, a critical future direction is 
characterizing the landscape of these neoepitope classes in human cancer. Functional 
validation investigating the extent to which high DAI peptides are predominant tumor 
rejection antigens in contexts other than B16-F10 melanoma will further determine the 
important of this neoepitope class. In summary, it will be important to evaluate 
neoepitope type and disease-specific immune context when considering therapies 
designed to augment T cell responses directed against neoepitopes. 
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CHAPTER 7 – Software 
Main functions from the Neoepitopes R package. 
Table 11. neoepitope_predictions function specification from the Neoepitopes R package. 
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Table 12. neoepitope_predictions_worker function specification from the Neoepitopes R 
package. 
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Table 13. neoepitopes_output function specification from the Neoepitopes R package. 
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